Updated on 2025/08/15

写真a

 
MATSUMOTO Yoshinori
 
Organization
Scheduled update Lecturer
Position
Lecturer
External link

Degree

  • 博士（医学） ( 2011.3   岡山大学 )

Research Interests

  • 免疫

  • Bone biology

  • Immunology

  • 骨代謝

Research Areas

  • Life Science / Connective tissue disease and allergy

  • Life Science / Immunology

Education

  • Okayama University   医歯薬学総合研究科   病態制御科学

    2008.4 - 2011.3

    　 More details

    Country： Japan

    researchmap

  • Okayama University    

    - 2011

    　 More details

  • Okayama University   医学部   医学科

    1997.4 - 2003.3

    　 More details

    Country： Japan

    researchmap

  • Okayama University    

    - 2003

    　 More details

Research History

  • 岡山大学学術研究院医療開発領域   診療科長

    2025.4

    　 More details

  • 岡山大学病院   研究准教授

    2023.4

    　 More details

  • 岡山大学学術研究院医歯薬学域   研究准教授

    2021.4

    　 More details

  • 岡山大学病院   副センター長

    2021.2

    　 More details

  • 岡山大学大学院医歯薬学総合研究科   研究准教授

    2020.4

    　 More details

  • 岡山大学病院   診療科副科長

    2019.7

    　 More details

  • Okayama University   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences   Assistant Professor

    2017.4

    　 More details

  • Scientific Associate,University of Toronto

    2016.4 - 2017.3

    　 More details

  • Japan Society for Promotion of Science

    2014.4 - 2016.3

    　 More details

  • Postdoctoral Fellow,University of Toronto

    2011.10 - 2016.3

    　 More details

  • Okayama University   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences   Graduate student(doctorate program)

    2008.4 - 2011.3

    　 More details

  • 尾道市立市民病院   内科医師

    2005.4 - 2008.3

    　 More details

  • 住友別子病院   内科医師

    2003.5 - 2005.3

    　 More details

▼display all

Professional Memberships

▼display all

Committee Memberships

  • 日本脊椎関節炎学会   評議員  

    2024.4   

    　 More details

  • 日本骨代謝学会   評議員  

    2023.12   

    　 More details

  • 日本脊椎関節炎学会   編集委員  

    2023.6   

    　 More details

  • 日本リウマチ学会   中国・四国支部運営委員  

    2022.12   

    　 More details

  • 日本炎症・再生医学会   評議員  

    2022.7   

    　 More details

  • 日本炎症・再生医学会   Young Investigator Committee委員  

    2022.4   

    　 More details

  • 日本臨床免疫学会   Midwinter seminarチューター  

    2021.10   

    　 More details

  • 日本リウマチ学会   評議員  

    2021.4   

    　 More details

  • 日本骨代謝学会   Young Investigator Committee委員  

    2020.2   

    　 More details

  • 日本内科学会   中国支部評議員  

    2017.6   

    　 More details

    Committee type：Academic society

    日本内科学会

    researchmap

▼display all

 

Papers

  • PARsylation-mediated ubiquitylation: lessons from rare hereditary disease Cherubism. International journal

    Yoshinori Matsumoto, Robert Rottapel

    Trends in molecular medicine   29 ( 5 )   390 - 405   2023.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Modification of proteins by ADP-ribose (PARsylation) is catalyzed by the poly(ADP-ribose) polymerase (PARP) family of enzymes exemplified by PARP1, which controls chromatin organization and DNA repair. Additionally, PARsylation induces ubiquitylation and proteasomal degradation of its substrates because PARsylation creates a recognition site for E3-ubiquitin ligase. The steady-state levels of the adaptor protein SH3-domain binding protein 2 (3BP2) is negatively regulated by tankyrase (PARP5), which coordinates ubiquitylation of 3BP2 by the E3-ligase ring finger protein 146 (RNF146). 3BP2 missense mutations uncouple 3BP2 from tankyrase-mediated negative regulation and cause Cherubism, an autosomal dominant autoinflammatory disorder associated with craniofacial dysmorphia. In this review, we summarize the diverse biological processes, including bone dynamics, metabolism, and Toll-like receptor (TLR) signaling controlled by tankyrase-mediated PARsylation of 3BP2, and highlight the therapeutic potential of this pathway.

    DOI： 10.1016/j.molmed.2023.02.001

    PubMed

    researchmap

  • Pharmacologic inhibition of PARP5, but not that of PARP1 or 2, promotes cytokine production and osteoclastogenesis through different pathways. International journal

    Yosuke Asano, Yoshinori Matsumoto, Fang He, Takayuki Katsuyama, Eri Katsuyama, Shigetomo Tsuji, Hiroshi Kamioka, Jose La Rose, Robert Rottapel, Jun Wada

    Clinical and experimental rheumatology   41 ( 9 )   1735 - 1745   2023.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVES: PARPs, which are members of the poly(ADP-ribose) polymerase superfamily, promote tumorigenesis and tumour-associated inflammation and are thus therapeutic targets for several cancers. The aim of the present study is to investigate the mechanistic insight into the roles PARPs for inflammation. METHODS: Primary murine macrophages were cultured in the presence or absence of the PARP5 inhibitor NVP-TNKS656 to examine the role of PARP5 for cytokine production. RESULTS: In contrast to the roles of other PARPs for induction of inflammation, we found in the present study that pharmacologic inhibition of PARP5 induces production of inflammatory cytokines in primary murine macrophages. We found that treatment with the PARP5 inhibitor NVP-TNKS656 in macrophages enhanced steady-state and LPS-mediated cytokine production through degradation of IκBα and subsequent nuclear translocation of NF-κB. We also found that pharmacologic inhibition of PARP5 stabilises the adaptor protein 3BP2, a substrate of PARP5, and that accelerated cytokine production induced by PARP5 inhibition was rescued in 3BP2-deleted macrophages. Additionally, we found that LPS increases the expression of 3BP2 and AXIN1, a negative regulator of β-catenin, through suppression of PARP5 transcripts in macrophages, leading to further activation of cytokine production and inhibition of β-catenin-mediated cell proliferation, respectively. Lastly, we found that PARP5 inhibition in macrophages promotes osteoclastogenesis through stabilisation of 3BP2 and AXIN1, leading to activation of SRC and suppression of β-catenin, respectively. CONCLUSIONS: Our results show that pharmacologic inhibition of PARP5 against cancers unexpectedly induces adverse autoinflammatory side effects through activation of innate immunity, unlike inhibition of other PARPs.

    DOI： 10.55563/clinexprheumatol/qf55h8

    PubMed

    researchmap

  • E3-ubiquitin ligases and recent progress in osteoimmunology. International journal

    Yosuke Asano, Yoshinori Matsumoto, Jun Wada, Robert Rottapel

    Frontiers in immunology   14   1120710 - 1120710   2023

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Ubiquitin-mediated proteasomal degradation is a post-transcriptional protein modification that is comprised of various components including the 76-amino acid protein ubiquitin (Ub), Ub-activating enzyme (E1), Ub-conjugating enzyme (E2), ubiquitin ligase (E3), deubiquitinating enzyme (DUB) and proteasome. We and others have recently provided genetic evidence showing that E3-ubiquitin ligases are associated with bone metabolism, the immune system and inflammation through ubiquitylation and subsequent degradation of their substrates. Dysregulation of the E3-ubiquitin ligase RNF146-mediated degradation of the adaptor protein 3BP2 (SH3 domain-binding protein 2) causes cherubism, an autosomal dominant disorder associated with severe inflammatory craniofacial dysmorphia syndrome in children. In this review, on the basis of our discoveries in cherubism, we summarize new insights into the roles of E3-ubiquitin ligases in the development of human disorders caused by an abnormal osteoimmune system by highlighting recent genetic evidence obtained in both human and animal model studies.

    DOI： 10.3389/fimmu.2023.1120710

    PubMed

    researchmap

  • Tankyrase represses autoinflammation through the attenuation of TLR2 signaling. International journal

    Yoshinori Matsumoto, Ioannis D Dimitriou, Jose La Rose, Melissa Lim, Susan Camilleri, Napoleon Law, Hibret A Adissu, Jiefei Tong, Michael F Moran, Andrzej Chruscinski, Fang He, Yosuke Asano, Takayuki Katsuyama, Ken-Ei Sada, Jun Wada, Robert Rottapel

    The Journal of clinical investigation   132 ( 7 )   2022.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Dysregulation of Toll-like receptor (TLR) signaling contributes to the pathogenesis of autoimmune diseases. Here, we provide genetic evidence that tankyrase, a member of the poly(ADP-ribose) polymerase (PARP) family, negatively regulates TLR2 signaling. We show that mice lacking tankyrase in myeloid cells developed severe systemic inflammation with high serum inflammatory cytokine levels. We provide mechanistic evidence that tankyrase deficiency resulted in tyrosine phosphorylation and activation of TLR2 and show that phosphorylation of tyrosine 647 within the TIR domain by SRC and SYK kinases was critical for TLR2 stabilization and signaling. Last, we show that the elevated cytokine production and inflammation observed in mice lacking tankyrase in myeloid cells were dependent on the adaptor protein 3BP2, which is required for SRC and SYK activation. These data demonstrate that tankyrase provides a checkpoint on the TLR-mediated innate immune response.

    DOI： 10.1172/JCI140869

    PubMed

    researchmap

  • RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion International journal

    Fang He, Yoshinori Matsumoto, Yosuke Asano, Yuriko Yamamura, Takayuki Katsuyama, Jose La Rose, Nahoko Tomonobu, Ni Luh Gede Yoni Komalasari, Masakiyo Sakaguchi, Robert Rottapel, Jun Wada

    FRONTIERS IN ONCOLOGY   11   729192 - 729192   2021.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3389/fonc.2021.665273

    Web of Science

    PubMed

    researchmap

  • Endonuclease increases efficiency of osteoblast isolation from murine calvariae International journal

    Yosuke Asano, Yoshinori Matsumoto, Jose La Rose, Fang He, Takayuki Katsuyama, Wang Ziyi, Shigetomo Tsuji, Hiroshi Kamioka, Robert Rottapel, Jun Wada

    SCIENTIFIC REPORTS   11 ( 1 )   8502 - 8502   2021.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-021-87716-8

    Web of Science

    PubMed

    researchmap

  • Takayasu phlebitis

    Yu Katayama, Yoshinori Matsumoto, Yuriko Yamamura, Yosuke Asano, Keigo Hayashi, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Mariko Narazaki, Ken-Ei Sada, Jun Wada

    RHEUMATOLOGY   59 ( 12 )   E131 - E133   2020.12

    　More details

  • Haploinsufficiency of RREB1 causes a Noonan-like RASopathy via epigenetic reprogramming of RAS-MAPK pathway genes

    Oliver A. Kent, Manipa Saha, Etienne Coyaud, Helen E. Burston, Napoleon Law, Keith Dadson, Sujun Chen, Estelle M. Laurent, Jonathan St-Germain, Ren X. Sun, Yoshinori Matsumoto, Justin Cowen, Aaryn Montgomery-Song, Kevin R. Brown, Charles Ishak, Jose La Rose, Daniel D. De Carvalho, Housheng Hansen He, Brian Raught, Filio Billia, Peter Kannu, Robert Rottapel

    NATURE COMMUNICATIONS   11 ( 1 )   2020.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41467-020-18483-9

    Web of Science

    researchmap

  • Basic and clinical associations between bone and cancer. International journal

    Fang He, Yoshinori Matsumoto

    Immunological medicine   43 ( 3 )   103 - 106   2020.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Bone is one of the most common distant organs in which tumor cells tend to metastasize depending on complicated immune system and bone microenvironments. Clinical symptoms such as severe pain and bone fractures associated with bone metastases severely affect patients' quality of life. According to the pathological types of bone destruction caused by the biological characteristics of different primary cancer cells, bone metastases are classified as osteolytic, osteoblastic and mixed types. Herein, we discuss the molecular mechanisms of bone metastasis and the therapeutic strategy with focus on bone metabolism.

    DOI： 10.1080/25785826.2020.1754084

    PubMed

    researchmap

  • Simultaneous development of IgA vasculitis and eosinophilic granulomatosis with polyangiitis. International journal

    Yosuke Asano, Yoshinori Matsumoto, Tatsuhiko Miyazaki, Akihiro Ishizu, Shin Morizane, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Yoshia Miyawaki, Michiko Morishita, Keiji Ohashi, Haruki Watanabe, Katsue Sunahori Watanabe, Tomoko Kawabata, Ken-Ei Sada, Hirofumi Makino, Jun Wada

    Modern rheumatology case reports   4 ( 1 )   63 - 69   2020.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Immunoglobulin A (IgA) vasculitis (IgAV) is a small vessel vasculitis presenting cutaneous purpura, arthralgias and/or arthritis, acute enteritis and glomerulonephritis caused by deposition of the IgA1-mediated immune complex. Eosinophilic granulomatosis with polyangiitis (EGPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) characterised by eosinophil-rich and granulomatous inflammation in small to medium-sized vessels. Both IgAV and EGPA are classified as autoimmune systemic vasculitis, but the pathogenesis of immune complex-mediated IgAV and that of pauci-immune EGPA are different. Here we report a rare case of simultaneous development of IgAV and EGPA presenting palpable purpura and numbness in a patient with a history of asthma. Histological examination revealed leukocytoclastic vasculitis with deposition of IgA, IgM and C3 in the upper dermis and necrotising vasculitis with eosinophilic infiltration and granulomatous formation in the lower dermis and subcutaneous fat, indicating the existence of IgAV and EGPA. Our case provides evidence of concurrent development of two different types of vasculitis, which may affect disease-associated complications, therapeutic strategy and prognosis.

    DOI： 10.1080/24725625.2019.1673528

    PubMed

    researchmap

  • Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib. International journal

    Yuriko Yamamura, Yoshinori Matsumoto, Yosuke Asano, Yu Katayama, Keigo Hayashi, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Mariko Takano-Narazaki, Ken-Ei Sada, Jun Wada

    Rheumatology advances in practice   4 ( 1 )   rkz050   2020

    　More details

  • Ubiquitin ligase RNF146 coordinates bone dynamics and energy metabolism Reviewed

    Yoshinori Matsumoto, Jose La Rose, Melissa Lim, Hibret A. Adissu, Napoleon Law, Xiaohong Mao, Feng Cong, Paula Mera, Gerard Karsenty, David Goltzman, Adele Changoor, Lucia Zhang, Megan Stajkowski, Marc D. Grynpas, Carsten Bergmann, Robert Rottapel

    The Journal of clinical investigation   127 ( 7 )   2612 - 2625   2017.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1172/JCI92233

    Web of Science

    PubMed

    researchmap

  • RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146 Reviewed

    Yoshinori Matsumoto, Jose Larose, Oliver A. Kent, Melissa Lim, Adele Changoor, Lucia Zhang, Yaryna Storozhuk, Xiaohong Mao, Marc D. Grynpas, Feng Cong, Robert Rottapel

    The Journal of clinical investigation   127 ( 4 )   1303 - 1315   2017.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1172/JCI90527

    Web of Science

    PubMed

    researchmap

  • Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2 Reviewed

    Yoshinori Matsumoto, Jose La Rose, Oliver A. Kent, Melany J. Wagner, Masahiro Narimatsu, Aaron D. Levy, Mitchell H. Omar, Jiefei Tong, Jonathan R. Krieger, Emily Riggs, Yaryna Storozhuk, Julia Pasquale, Manuela Ventura, Behzad Yeganeh, Martin Post, Michael F. Moran, Marc D. Grynpas, Jeffrey L. Wrana, Giulio Superti-Furga, Anthony J. Koleske, Ann Marie Pendergast, Robert Rottapel

    The Journal of clinical investigation   126 ( 12 )   4482 - 4496   2016.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1172/JCI87802

    Web of Science

    PubMed

    researchmap

  • Estrogen facilitates osteoblast differentiation by upregulating bone morphogenetic protein-4 signaling Reviewed

    Yoshinori Matsumoto, Fumio Otsuka, Mariko Takano-Narazaki, Takayuki Katsuyama, Eri Nakamura, Naoko Tsukamoto, Kenichi Inagaki, Ken-Ei Sada, Hirofumi Makino

    Steroids   78 ( 5 )   513 - 520   2013.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.steroids.2013.02.011

    Scopus

    PubMed

    researchmap

  • An in vivo role of bone morphogenetic protein-6 in aldosterone production by rat adrenal gland Reviewed

    Yoshinori Matsumoto, Fumio Otsuka, Kenichi Inagaki, Naoko Tsukamoto, Mariko Takano-Narazaki, Tomoko Miyoshi, Eri Nakamura, Kanako Ogura-Ochi, Masaya Takeda, Hirofumi Makino

    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY   132 ( 1-2 )   8 - 14   2012.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jsbmb.2012.04.004

    Web of Science

    PubMed

    researchmap

  • Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients Reviewed

    Yoshinori Matsumoto, Ken-ei Sada, Fumio Otsuka, Mariko Takano, Noriko Toyota, Koichi Sugiyama, Hiroshi Wakabayashi, Tomoko Kawabata, Hirofumi Makino

    RHEUMATOLOGY INTERNATIONAL   32 ( 10 )   2999 - 3005   2012.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s00296-011-2136-z

    Web of Science

    PubMed

    researchmap

  • Bone morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via Smad2/3 pathway by counteracting Smad1/5/8 signaling Reviewed

    Yoshinori Matsumoto, Fumio Otsuka, Jun Hino, Tomoko Miyoshi, Mariko Takano, Mikiya Miyazato, Hirofumi Makino, Kenji Kangawa

    MOLECULAR AND CELLULAR ENDOCRINOLOGY   350 ( 1 )   78 - 86   2012.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.mce.2011.11.023

    Web of Science

    PubMed

    researchmap

  • Risk Factors for Infection in Patients with Remitted Rheumatic Diseases Treated with Glucocorticoids Reviewed

    Yoshinori Matsumoto, Ken-ei Sada, Mariko Takano, Noriko Toyota, Ryutaro Yamanaka, Koichi Sugiyama, Hiroshi Wakabayashi, Tomoko Kawabata, Fumio Otsuka, Hirofumi Makino

    ACTA MEDICA OKAYAMA   65 ( 5 )   329 - 334   2011.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.18926/AMO/47015

    Web of Science

    PubMed

    researchmap

  • Systemic Lupus Erythematosus Complicated with Acute Myocardial Infarction and Ischemic Colitis Reviewed

    Yoshinori Matsumoto, Hiroshi Wakabayashi, Fumio Otsuka, Kentaro Inoue, Mariko Takano, Ken-ei Sada, Hirofumi Makino

    INTERNAL MEDICINE   50 ( 21 )   2669 - 2673   2011

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.2169/internalmedicine.50.5966

    Web of Science

    PubMed

    researchmap

  • Estrogen and glucocorticoid regulate osteoblast differentiation through the interaction of bone morphogenetic protein-2 and tumor necrosis factor-alpha in C2C12 cells Reviewed

    Yoshinori Matsumoto, Fumio Otsuka, Mariko Takano, Tomoyuki Mukai, Ryutaro Yamanaka, Masaya Takeda, Tomoko Miyoshi, Kenichi Inagaki, Ken-ei Sada, Hirofumi Makino

    MOLECULAR AND CELLULAR ENDOCRINOLOGY   325 ( 1-2 )   118 - 127   2010.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.mce.2010.05.004

    Web of Science

    PubMed

    researchmap

  • PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy

    Kazuya Matsumoto, Yoshinori Matsumoto, Jun Wada

    Frontiers in Immunology   16   2025.3

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Frontiers Media SA  

    Poly-ADP-ribosylation (PARylation) is a post-translational modification in which ADP-ribose is added to substrate proteins. PARylation is mediated by a superfamily of ADP-ribosyl transferases known as PARPs and influences a wide range of cellular functions, including genome integrity maintenance, and the regulation of proliferation and differentiation. We and others have recently reported that PARylation of SH3 domain-binding protein 2 (3BP2) plays a role in bone metabolism, immune system regulation, and cytokine production. Additionally, PARylation has recently gained attention as a target for cancer treatment. In this review, we provide an overview of PARylation, its involvement in several signaling pathways related to cancer immunity, and the potential of combination therapies with PARP inhibitors and immune checkpoint inhibitors.

    DOI： 10.3389/fimmu.2025.1537615

    researchmap

  • Comparison of different ANCA detection methods in a predominantly MPO-ANCA-associated vasculitis cohort. International journal

    Yasuhiro Katsumata, Ken-Ei Sada, Tomohiro Kameda, Hiroaki Dobashi, Shinya Kaname, Naotake Tsuboi, Yoshinori Matsumoto, Koichi Amano, Naoto Tamura, Masayoshi Harigai

    Immunological medicine   48 ( 1 )   47 - 57   2025.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We compared different antineutrophil cytoplasmic antibody (ANCA) detection methods using a predominantly myeloperoxidase (MPO)-ANCA-associated vasculitis cohort. Stored sera from 147 patients with untreated ANCA-associated vasculitis (AAV), including microscopic polyangiitis and granulomatosis with polyangiitis (n = 115 and 32, respectively), and 124 disease controls were tested for P-ANCA and C-ANCA with immunofluorescence (IIF), and for MPO-ANCA and proteinase 3 (PR3)-ANCA with different antigen-specific immunoassays: direct enzyme-linked immunosorbent assay (ELISA), chemiluminescent enzyme immunoassay (CLEIA), third-generation fluorescent enzyme immunoassay (FEIA), and latex turbidimetrical immunoassay (LTIA). In addition, MPO-ANCA and PR3-ANCA titers were calibrated using certified reference materials (CRMs). The sensitivities and specificities for AAV diagnoses were 95% and 94% (IIF), 86% and 98% (ELISA), 93% and 94% (CLEIA), 92% and 96% (FEIA), and 68% and 88% (LTIA). Dual IIF/antigen-specific immunoassay testing reduced diagnostic accuracies from 94% to 93%. The quantitative agreement between ANCA levels measured using CLEIA and FEIA and calibrated using CRMs was not good. In conclusion, this study demonstrated the high performance of antigen-specific immunoassays for AAV diagnosis in a predominantly MPO-ANCA-associated vasculitis cohort and suggested that the benefit of dual IIF/antigen-specific immunoassay testing is limited. Standardizing ANCA measurements using different immunoassays was difficult, even when using CRMs.

    DOI： 10.1080/25785826.2024.2408054

    PubMed

    researchmap

  • Dyspnea with Hemidiaphragm Elevation in a Patient with Giant Cell Arteritis: A Case Report

    Yosuke Asano, Yoshinori Matsumoto, Natsuki Kubota, Yuya Terajima, Kazuya Matsumoto, Kenta Shidahara, Kei Hirose, Takato Nakadoi, Shoichi Nawachi, Yu Katayama, Yoshia Miyawaki, Eri Katsuyama, Takayuki Katsuyama, Mariko Takano-Narazaki, Ken-Ei Sada, Jun Wada

    Internal Medicine   2025

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Japanese Society of Internal Medicine  

    DOI： 10.2169/internalmedicine.4055-24

    researchmap

  • Pericardial artery lymphoma in a patient with dermatomyositis: A case report. International journal

    Kei Hirose, Takayuki Katsuyama, Natsuki Kubota, Yuya Terajima, Kazuya Matsumoto, Kenta Shidahara, Takato Nakadoi, Shoichi Nawachi, Yu Katayama, Yoshia Miyawaki, Eri Katsuyama, Mariko Narazaki-Takano, Yoshinori Matsumoto, Noboru Asada, Ken-Ei Sada, Jun Wada

    Modern rheumatology case reports   2024.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A woman in her 60s presented with erythema on both elbows, dyspnea on exertion, discomfort, and swelling of the left upper extremity, followed by swelling and myalgia of the right upper and lower extremities. She was diagnosed with anti-TIF1γ antibody-positive dermatomyositis with interstitial pneumonia. The initial screening tests for malignant diseases including contrast-enhanced CT, upper and lower endoscopy, and gynecological examination did not reveal any obvious abnormalities. The patient experienced two recurrent episodes of muscle weakness and dysphagia during treatment with intravenous glucocorticoids and cyclophosphamide. Five months after diagnosis, a bone marrow biopsy and positron emission tomography- computed tomography (PET-CT) scan revealed a coronary malignant lymphoma with suspected systemic metastasis. Although chemotherapy was initiated, the patient ultimately succumbed to alveolar hemorrhage. Coronary lymphoma is very rare and there has been no report of a cases associated with myositis. PET-CT may be useful for searching malignancy in anti-TIF1γ antibody-positive dermatomyositis cases of recurrent relapse.

    DOI： 10.1093/mrcr/rxae065

    PubMed

    researchmap

  • Association between discontinuity of care and patient trust in the usual rheumatologist among patients with systemic lupus erythematosus: a cross-sectional study

    Yu Katayama, Yoshia Miyawaki, Kenta Shidahara, Shoichi Nawachi, Yosuke Asano, Eri Katsuyama, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Nao Oguro, Nobuyuki Yajima, Yuichi Ishikawa, Natsuki Sakurai, Chiharu Hidekawa, Ryusuke Yoshimi, Shigeru Ohno, Takanori Ichikawa, Dai Kishida, Yasuhiro Shimojima, Ken-ei Sada, Jun Wada, David H. Thom, Noriaki Kurita

    Arthritis Research & Therapy   26 ( 1 )   2024.11

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1186/s13075-024-03428-0

    researchmap

    Other Link： https://link.springer.com/article/10.1186/s13075-024-03428-0/fulltext.html

  • Successful treatment for life threatening recurrent non-traumatic rectus sheath hematoma in a case with microscopic polyangiitis with rapidly progressive glomerulonephritis.

    Hiroyuki Nakanoh, Hidemi Takeuchi, Morimoto Shiho, Yuya Terajima, Shugo Okamoto, Yasuhiro Onishi, Keiko Tanaka, Takayuki Katsuyama, Kenji Tsuji, Yoshinori Matsumoto, Katsuyuki Tanabe, Hiroshi Morinaga, Mayu Uka, Koji Tomita, Haruhito A Uchida, Takao Hiraki, Jun Wada

    Internal medicine (Tokyo, Japan)   2024.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A 68-year-old woman was admitted to our hospital because of a rapid progression of renal dysfunction with positive myeloperoxidase antineutrophil cytoplasmic antibody and was diagnosed with rapidly progressive glomerulonephritis associated with microscopic polyangiitis (MPA). Severe right rectus sheath hematoma (RSH) bleeding from the inferior epigastric artery developed after starting hemodialysis, which required 4 transarterial embolizations due to recurrent bleeding. After additional treatment with methylprednisolone pulse therapy and rituximab, no rebleeding occurred. Although the giant hematoma reached the pelvis, it shrank spontaneously without any intervention. Nontraumatic RSH should therefore be considered when treating patients with multiple risk factors.

    DOI： 10.2169/internalmedicine.3239-23

    PubMed

    researchmap

  • Discontinuity of care and trust in usual physician among patients with systemic lupus erythematosus

    Katayama Yu, Miyawaki Yoshia, Shidahara Kenta, Nawachi Shoichi, Asano Yosuke, Katsuyama Eri, Katsuyama Takayuki, Takano-Narazaki Mariko, Matsumoto Yoshinori, Oguro Nao, Ishikawa Yuichi, Sakurai Natsuki, Hidekawa Chiharu, Ohno Shigeru, Ichikawa Takanori, Kishida Dai, Shimojima Yasuhiro, Sada Ken-ei, Wada Jun, Thom David, Kurita Noriaki† (†last author)

    medRxiv   2024.03.13.24304255   2024.3

    　More details

  • 二次性の結節性多発動脈炎の発症したびまん性大細胞型B細胞性リンパ腫の一例

    久保田 菜月, 宮脇 義亜, 寺嶋 悠也, 松本 和也, 廣瀬 啓, 志田原 健太, 中土井 崇人, 縄稚 翔一, 片山 祐, 勝山 隆行, 勝山 恵理, 楢崎 真理子, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   821 - 821   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 中小型血管炎:治療3 リツキシマブ1000mgの2回投与により寛解導入を行なった初発の顕微鏡的多発血管炎および多発血管炎性肉芽腫症の8例に関する記述研究

    松本 和也, 宮脇 義亜, 久保田 菜月, 寺嶋 悠也, 廣瀬 啓, 志田原 健太, 中土井 崇人, 縄稚 翔一, 片山 祐, 勝山 隆行, 勝山 恵理, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   581 - 581   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 上腸間膜動脈周囲軟部影から血管炎が疑われたが膵癌と判明した一例

    志田原 健太, 片山 祐, 久保田 菜月, 寺嶋 悠也, 松本 和也, 廣瀬 啓, 中土井 崇人, 縄稚 翔一, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   881 - 881   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 漿液性網膜剥離と蛋白漏出胃腸症を合併した全身性エリテマトーデスの一例

    都 明希, 勝山 隆行, 久保田 菜月, 寺嶋 悠也, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 片山 祐, 宮脇 義亜, 勝山 恵理, 楢崎 真理子, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   914 - 914   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • Pseudo pseudo Meigs syndromeを呈したSLEの1例

    中山 菜々子, 片山 祐, 久保田 菜月, 寺嶋 悠也, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   914 - 914   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 婦人科悪性腫瘍の摘出後,速やかにCKが正常化したHMGCR抗体陽性壊死性ミオパチーの一例

    古山 怜奈, 勝山 恵理, 久保田 菜月, 寺嶋 悠也, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 片山 祐, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   915 - 915   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • TAFRO症候群に緩徐進行1型糖尿病を合併した1例

    喜舎場 朝基, 片山 祐, 久保田 菜月, 寺嶋 悠也, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   914 - 914   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 不全型ベーチェット病に急性尿細管間質性腎炎を合併した一例

    有地 萌音, 勝山 恵理, 久保田 菜月, 寺嶋 悠也, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 片山 祐, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   909 - 909   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 好酸球性多発血管炎性肉芽腫症(EGPA)との鑑別に苦慮した好酸球性大腸炎(EoC)の一例

    寺嶋 悠也, 宮脇 義亜, 久保田 菜月, 松本 和也, 廣瀬 啓, 志田原 健太, 中土井 崇人, 縄稚 翔一, 片山 祐, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   889 - 889   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 重症感染症を合併した難治性中小型血管炎に対してアバコパンとγグロブリン大量静注療法(IVIG)で寛解導入に至った1例

    小松原 悠, 松本 佳則, 久保田 菜月, 寺嶋 悠也, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 片山 祐, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   913 - 913   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 骨免疫制御蛋白に着目した関節リウマチ病態形成メカニズムの解明

    三前 英恵, 松本 佳則, 松本 和也, 浅野 洋介, 久保田 菜月, 寺嶋 悠也, 廣瀬 啓, 縄稚 翔一, 志田原 健太, 中土井 崇人, 片山 祐, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   68回   910 - 910   2024.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • The first presentation of a case of nail-patella syndrome newly diagnosed at the onset of rheumatoid arthritis: a case report. International journal

    Kazuya Matsumoto, Yoshinori Matsumoto, Shoichi Nawachi, Yosuke Asano, Yu Katayama, Yoshia Miyawaki, Takayuki Katsuyama, Eri Katsuyama, Yoshihisa Nasu, Ken-Ei Sada, Jun Wada

    BMC musculoskeletal disorders   25 ( 1 )   139 - 139   2024.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Nail-patella syndrome (NPS) is a rare autosomal dominant disorder that is characterized by dysplasia of the nails, hypoplasia and/or dislocation of the patella and the presence of iliac horns. Using the CARE guidelines, we present the first reported case of NPS that was newly diagnosed at the onset of rheumatoid arthritis (RA). CASE PRESENTATION: A 74-year-old man was admitted to our hospital due to an 8-month history of arthralgia in bilateral wrists, elbows and fingers. He had a past history of glaucoma and left patella dislocation that had been operatively recentered at the age of 15 years. Laboratory data showed elevated levels of serum C-reactive protein and rheumatoid factor and an elevated titer of anti-SS-A antibodies, while estimated glomerular filtration rate (eGFR), titers of other antibodies and the results of a urinary test were normal. An X-ray showed deformity of bilateral radial heads and the right elbow, and magnetic resonance imaging (MRI) of his hands showed synovitis and erosion in the multiple swollen joints of the wrists and fingers. In addition to these typical features of RA, he had bilateral thumb nail dysplasia with mild hypoplasia of bilateral patellae and iliac horns as shown by the X-ray. He was diagnosed as having autosomal dominant disorder NPS co-existing with RA and he was treated with methotrexate in combination with an oral Janus kinase (JAK) inhibitor, leading to induction of remission. CONCLUSIONS: We have presented a rare case of NPS that was newly diagnosed at the onset of RA. Clinical and radiographic findings of NPS are highlighted in this case report for diagnosing NPS on the basis of typical manifestations.

    DOI： 10.1186/s12891-024-07242-2

    PubMed

    researchmap

  • Infliximab biosimilar-induced lupus nephritis: A case report. International journal

    Kenta Shidahara, Takayuki Katsuyama, Kei Hirose, Kazuya Matsumoto, Shoichi Nawachi, Takato Nakadoi, Yosuke Asano, Yu Katayama, Yoshia Miyawaki, Eri Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Jun Wada

    Modern rheumatology case reports   2023.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We present a case of microhematuria, proteinuria and hypocomplementemia that developed in a 55-year-old female who was being treated with an infliximab biosimilar (IFX-BS) for rheumatoid arthritis (RA). Renal biopsy showed lupus nephritis (ISN/RPS classification class IV+V). Treatment with the IFX-BS was discontinued, and treatment with prednisolone, hydroxychloroquine and abatacept was started, resulting in clinical remission of lupus nephritis and RA. Although tumor necrosis factor-α (TNF-α) inhibitors are known to induce production of autoantibodies, symptoms are usually limited to skin involvement or arthritis, and renal complications are rare. Physicians should be aware of the risk of lupus nephritis and carefully monitor patients for the development of renal involvement during treatment with TNF-α inhibitors.

    DOI： 10.1093/mrcr/rxad061

    PubMed

    researchmap

  • Immunosuppressive Treatment for an anti-U1 Ribonucleoprotein Antibody-positive Patient with Pulmonary Arterial Hypertension: A Case Report.

    Kazuya Matsumoto, Yoshia Miyawaki, Takayuki Katsuyama, Takato Nakadoi, Kenta Shidahara, Kei Hirose, Shoichi Nawachi, Yosuke Asano, Yu Katayama, Eri Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Atsushi Mori, Satoshi Akagi, Ken-Ei Sada, Jun Wada

    Internal medicine (Tokyo, Japan)   2023.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A 34-year-old woman with pulmonary arterial hypertension (PAH) was admitted to the hospital. She had been diagnosed with PAH three years earlier and treated with triple vasodilator therapy. She was positive for anti-U1 ribonucleoprotein antibodies but did not show any other symptoms associated with autoimmune diseases. Corticosteroid and cyclophosphamide therapy was administered, suspecting the involvement of immunological pathophysiology. After 3 weeks, the mean pulmonary artery pressure decreased from 50 to 38 mmHg without any change in the vasodilators. Immunosuppressive therapy was effective in this patient with PAH with an anti-U1 ribonucleoprotein-antibody-positive response and might be an option for patients with these specific features.

    DOI： 10.2169/internalmedicine.1407-22

    PubMed

    researchmap

  • The Association of Grit With Burnout Components (Professional Efficacy, Exhaustion, and Cynicism) Among Academic Rheumatologists: The TRUMP2-SLE Study. International journal

    Yoshia Miyawaki, Ken-Ei Sada, Kenta Shidahara, Shoichi Nawachi, Yosuke Asano, Yu Katayama, Keigo Hayashi, Eri Katsuyama, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Nao Oguro, Nobuyuki Yajima, Yuichi Ishikawa, Natsuki Sakurai, Chiharu Hidekawa, Ryusuke Yoshimi, Takanori Ichikawa, Dai Kishida, Yasuhiro Shimojima, Jun Wada, Noriaki Kurita

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases   29 ( 6 )   268 - 274   2023.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVES: There is a high prevalence of burnout among rheumatologists. Grit, which is defined as possessing perseverance and a passion to achieve long-term goals, is predictive of success in many professions; however, whether grit is associated with burnout remains unclear, especially among academic rheumatologists, who have multiple simultaneous responsibilities. Thus, the purpose of this study was to examine the associations between grit and self-reported burnout components-professional efficacy, exhaustion, and cynicism-in academic rheumatologists. METHODS: This cross-sectional study involved 51 rheumatologists from 5 university hospitals. The exposure was grit, measured using mean scores for the 8-item Short Grit Scale (range, 1-5 [5 = extremely high grit]). The outcome measures were mean scores for 3 burnout domains (exhaustion, professional efficacy, and cynicism; range, 1-6; measured using the 16-item Maslach Burnout Inventory-General Survey). General linear models were fitted with covariates (age, sex, job title [associate professor or higher vs lower], marital status, and having children). RESULTS: Overall, 51 physicians (median age, 45 years; interquartile range, 36-57; 76% men) were included. Burnout positivity was found in 68.6% of participants (n = 35/51; 95% confidence interval [CI], 54.1, 80.9). Higher grit was associated with higher professional efficacy (per 1-point increase; 0.51 point; 95% CI, 0.18, 0.84) but not with exhaustion or cynicism. Being male and having children were associated with lower exhaustion (-0.69; 95% CI, -1.28, -0.10; p = 0.02; and -0.85; 95% CI, -1.46, -0.24; p = 0.006). Lower job title (fellow or part-time lecturer) was associated with higher cynicism (0.90; 95% CI, 0.04, 1.75; p = 0.04). CONCLUSIONS: Grit is associated with higher professional efficacy among academic rheumatologists. To prevent burnout among staff, supervisors who manage academic rheumatologists should assess their staff's individual grit.

    DOI： 10.1097/RHU.0000000000001989

    PubMed

    researchmap

  • Amelioration of nephritis in receptor for advanced glycation end-products (RAGE)-deficient lupus-prone mice through neutrophil extracellular traps. International journal

    Haruki Watanabe, Masataka Kubo, Akihiko Taniguchi, Yosuke Asano, Sumie Hiramatsu-Asano, Keiji Ohashi, Sonia Zeggar, Eri Katsuyama, Takayuki Katsuyama, Katsue Sunahori-Watanabe, Ken-Ei Sada, Yoshinori Matsumoto, Yasuhiko Yamamoto, Hiroshi Yamamoto, Myoungsun Son, Jun Wada

    Clinical immunology (Orlando, Fla.)   250   109317 - 109317   2023.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The receptor for advanced glycation end-products (RAGE) is a pattern recognition receptor that regulates inflammation, cell migration, and cell fate. Systemic lupus erythematosus (SLE) is a chronic multiorgan autoimmune disease. To understand the function of RAGE in SLE, we generated RAGE-deficient (Ager-/-) lupus-prone mice by backcrossing MRL/MpJ-Faslpr/J (MRL-lpr) mice with Ager-/- C57BL/6 mice. In 18-week-old Ager-/- MRL-lpr, the weights of the spleen and lymph nodes, as well as the frequency of CD3+CD4-CD8- cells, were significantly decreased. Ager-/- MRL-lpr mice had significantly reduced urine albumin/creatinine ratios and markedly improved renal pathological scores. Moreover, neutrophil infiltration and neutrophil extracellular trap formation in the glomerulus were significantly reduced in Ager-/- MRL-lpr. Our study is the first to reveal that RAGE can have a pathologic role in immune cells, particularly neutrophils and T cells, in inflammatory tissues and suggests that the inhibition of RAGE may be a potential therapeutic strategy for SLE.

    DOI： 10.1016/j.clim.2023.109317

    PubMed

    researchmap

  • Association of alcohol consumption and fatigue in SLE: A cross-sectional study from Lupus Registry of Nationwide Institution (LUNA) cohort. International journal

    Yu Katayama, Yoshia Miyawaki, Kenta Shidahara, Shoichi Nawachi, Yosuke Asano, Keiji Ohashi, Eri Katsuyama, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Nobuyuki Yajima, Yasuhiro Shimojima, Ryusuke Yoshimi, Kunihiro Ichinose, Hiroshi Kajiyama, Michio Fujiwara, Shuzo Sato, Jun Wada

    Lupus   32 ( 4 )   9612033231159471 - 9612033231159471   2023.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: Fatigue is one of the most common complaints and is a potentially modifiable issue in systemic lupus erythematosus (SLE). Studies suggest that alcohol consumption has a protective effect against the development of SLE; however, an association between alcohol consumption and fatigue in patients with SLE has not been studied. Here, we assessed whether alcohol consumption was associated with fatigue using lupus patient-reported outcomes (LupusPRO). METHODS: This cross-sectional study, conducted between 2018 and 2019, included 534 patients (median age, 45 years; 87.3% female) from 10 institutions in Japan. The main exposure was alcohol consumption, which was defined as the frequency of drinking [<1 day/month (none group), ≤1 day/week (moderate group), and ≥2 days/week (frequent group)]. The outcome measure was the Pain Vitality domain score in LupusPRO. Multiple regression analysis was performed as the primary analysis after adjusting for confounding factors, such as age, sex, and damage. Subsequently, the same analysis was performed as a sensitivity analysis after multiple imputations (MIs) for missing data (n = 580). RESULTS: In total, 326 (61.0%) patients were categorized into the none group, 121 (22.7%) into the moderate group, and 87 (16.3%) into the frequent group. The frequent group was independently associated with less fatigue compared with none group [β = 5.98 (95% CI 0.19-11.76), p = 0.04], and the results did not substantially deviate after MI. CONCLUSIONS: Frequent drinking was associated with less fatigue, which highlights the need for further longitudinal studies focusing on drinking habits in patients with SLE.

    DOI： 10.1177/09612033231159471

    PubMed

    researchmap

  • A case of sitosterolaemia-caused systemic large-vessel stenosis mimicking Takayasu arteritis in which FDG-PET provided a clue for the differential diagnosis

    Takato Nakadoi, Eri Katsuyama, Kazuya Matsumoto, Kenta Shidahara, Kei Hirose, Shoichi Nawachi, Yosuke Asano, Yu Katayama, Yoshia Miyawaki, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Hayato Tada, Jun Wada

    Rheumatology Advances in Practice   7 ( 3 )   2023.1

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Oxford University Press (OUP)  

    DOI： 10.1093/rap/rkad096

    researchmap

    Other Link： https://academic.oup.com/rheumap/article-pdf/7/3/rkad096/53710646/rkad096.pdf

  • Grit personality of physicians and achievement of treatment goals in patients with systemic lupus erythematosus. International journal

    Ken-Ei Sada, Yoshia Miyawaki, Kenta Shidahara, Shoichi Nawachi, Yu Katayama, Yosuke Asano, Keigo Hayashi, Keiji Ohashi, Eri Katsuyama, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Nao Oguro, Yuichi Ishikawa, Natsuki Sakurai, Chiharu Hidekawa, Ryusuke Yoshimi, Dai Kishida, Takanori Ichikawa, Yasuhiro Shimojima, Noriaki Kurita, Nobuyuki Yajima

    Rheumatology (Oxford, England)   62 ( 6 )   2154 - 2159   2022.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVES: Although personality characteristics of patients with systemic lupus erythematosus (SLE) affect their disease activity and damage, it is unclear whether those of attending physicians affect the outcomes of patients with SLE. Grit is a personality trait for achieving long-term goals that may influence the decision-making for continuing treatment plans for patients. We aimed to evaluate the relationship between the grit of attending physicians and achievement of treatment goals in patients with SLE. METHODS: This cross-sectional study was conducted at five referral hospitals. The main exposure was "consistency of interest" and "perseverance of effort" of the attending physicians, measured by the Short Grit Scale. The primary outcome was achievement of a lupus low disease activity state (LLDAS). The association between physicians' grit score and LLDAS was analyzed by generalized estimating equation (GEE) logistic regression with cluster robust variance estimation with adjustment for confounders. RESULTS: The median (interquartile range) total, consistency, and perseverance scores of 37 physicians were 3.1 (2.9-3.6), 3.3 (2.8-3.8), and 3.3 (3.0-3.5), respectively. Among the 386 patients, 154 (40%) had achieved LLDAS. Low consistency score (≤2.75) in physicians was related to LLDAS achievement independently using GEE logistic regression. The score of the question "I often set a goal but later choose to pursue a different one" was significantly higher in patients achieving LLDAS. CONCLUSIONS: Difficulty of attending physicians to change treatment goals might be related to lower LLDAS achievement in patients with SLE.

    DOI： 10.1093/rheumatology/keac612

    PubMed

    researchmap

  • Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study. International journal

    Ken-Ei Sada, Yu Katayama, Yosuke Asano, Keigo Hayashi, Yoshia Miyawaki, Keiji Ohashi, Eri Katsuyama, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Nobuyuki Yajima

    Lupus science & medicine   9 ( 1 )   2022.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: It is still unclear how glucocorticoids (GCs) affect the long-term clinical course of patients with SLE. The objective of this study is to explore the factors associated with GC-free treatment status. METHODS: Using data from the lupus registry of nationwide institutions, GC dose at registration was compared between short, middle and long disease durations of <5, 5-20 and ≥20 years, respectively. After excluding patients who never used GC, we evaluated the relationship between GC-free status and chronic damage using Systemic Lupus International Collaborating Clinics Damage Index. RESULTS: GC doses at enrolment of the 1019 patients were as follows: GC-free in 101 (10%); 0<prednisolone (PSL) ≤5 mg/day in 411 (40%); 5<PSL ≤7.5 in 169 (17%); 7.5<PSL ≤10 in 194 (19%) and PSL≥10 in 144 (14%) patients. Of the patients who were not currently using GCs, patients who never used GC more frequently had short disease duration (66% with short, 23% with middle and 17% with long disease duration, p=0.00029). Univariate analysis of patients who underwent GC treatment showed that patients without GCs exhibited older age, lower disease activity, less immunosuppressant and hydroxychloroquine use and higher C3 levels. Among patients with a disease duration of ≥20 years, GC-free status was more frequent in patients without chronic damage (11% vs 4%, p=0.023). After adjusting for age, sex and disease activity, no chronic damage accrual was associated with GC-free status (OR 3.6, 95% CI 1.1 to 11.3). CONCLUSION: Even in the patients with long disease duration, one-point GC-free treatment status might be related to no chronic damage accrual.

    DOI： 10.1136/lupus-2022-000772

    PubMed

    researchmap

  • A case of recurrent IgG4-related disease successfully treated with belimumab after remission of systemic lupus erythematosus. International journal

    Yu Katayama, Takayuki Katsuyama, Kenta Shidahara, Shoichi Nawachi, Yosuke Asano, Keiji Ohashi, Yoshia Miyawaki, Eri Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Jun Wada

    Rheumatology (Oxford, England)   61 ( 10 )   e308-e310   2022.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1093/rheumatology/keac284

    PubMed

    researchmap

  • CD30-targeted therapy induces apoptosis of inflammatory cytokine-stimulated synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice. International journal

    Minami Matsuhashi, Keiichiro Nishida, Misa Sakamoto, Yuka Gion, Aki Yoshida, Takayuki Katsuyama, Ryuichi Nakahara, Yoshihisa Nasu, Yoshinori Matsumoto, Yasuharu Sato, Toshifumi Ozaki

    Inflammation research : official journal of the European Histamine Research Society ... [et al.]   71 ( 2 )   215 - 226   2022.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: It has been reported that levels of soluble CD30 in serum and joint fluid are significantly elevated in patients with rheumatoid arthritis (RA). This study aimed to investigate whether CD30 could be a therapeutic target for RA. METHODS: The expression and localization of CD30 were examined by immunohistochemical and double immunofluorescence staining on synovial tissue samples obtained from patients with RA or osteoarthritis (OA) during surgery. Changes in CD30 expression of fibroblast-like synoviocytes (FLS) from RA patients with or without TNFα and IL-1β stimulation were examined by the polymerase chain reaction (PCR) and flow cytometry. Collagen antibody-induced arthritis (CAIA) was created in DBA/1 mice, and the therapeutic effect of brentuximab vedotin (BV) was examined by clinical score, histological findings and measurement of serum levels of SAA, IL-6, and TNFα. RESULTS: CD30 expression was significantly higher in samples from patients with RA than from those with OA. Double immunofluorescence showed a low rate of co-localization of CD30 with CD20 or CD90, but a high rate of co-localization of CD30 and CD138. CD30 mRNA expression was upregulated 11.7-fold in FLS following stimulation by inflammatory cytokines. The clinical scores of CAIA mice were significantly lower following both BV treatments, however, the histological scores of CAIA mice were significantly lower only following treatment with high dose BV (70 mg/kg). CONCLUSIONS: CD30 was expressed on immunocompetent cells in synovial tissue from RA patients and in cytokine-stimulated FLS in vitro. High dose BV (70 mg/kg) showed significant therapeutic effects in ameliorating inflammation and joint destruction in CAIA mice, but low dose BV (30 mg/kg) was insufficient.

    DOI： 10.1007/s00011-021-01537-z

    PubMed

    researchmap

  • Real-world data on vitamin D supplementation and its impacts in systemic lupus erythematosus: Cross-sectional analysis of a lupus registry of nationwide institutions (LUNA). International journal

    Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Yu Katayama, Keiji Ohashi, Michiko Morishita, Yoshia Miyawaki, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Jun Wada

    PloS one   17 ( 6 )   e0270569   2022

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Although vitamin D concentration is reportedly associated with the pathogenesis and pathology of systemic lupus erythematosus (SLE), benefits of vitamin D supplementation in SLE patients have not been elucidated, to our knowledge. We investigated the clinical impacts of vitamin D supplementation in SLE. METHODS: A cross-sectional analysis was performed using data from a lupus registry of nationwide institutions. We evaluated vitamin D supplementation status associated with disease-related Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) as a parameter of long-term disease activity control. RESULTS: Of the enrolled 870 patients (mean age: 45 years, mean disease duration: 153 months), 426 (49%) received vitamin D supplementation. Patients with vitamin D supplementation were younger (43.2 vs 47.5 years, P < 0.0001), received higher doses of prednisolone (7.6 vs 6.8 mg/day, P = 0.002), and showed higher estimated glomerular filtration rates (79.3 vs 75.3 mL/min/1.73m2, P = 0.02) than those without supplementation. Disease-related SDI (0.73 ± 1.12 vs 0.73 ± 1.10, P = 0.75), total SDI, and SLE Disease Activity Index (SLEDAI) did not significantly differ between patients receiving and not receiving vitamin D supplementation. Even after excluding 136 patients who were highly recommended vitamin D supplementation (with age ≥ 75 years, history of bone fracture or avascular necrosis, denosumab use, and end-stage renal failure), disease-related SDI, total SDI, and SLEDAI did not significantly differ between the two groups. CONCLUSIONS: Even with a possible Vitamin D deficiency and a high risk of bone fractures in SLE patients, only half of our cohort received its supplementation. The effect of vitamin D supplementation for disease activity control was not observed.

    DOI： 10.1371/journal.pone.0270569

    PubMed

    researchmap

  • Adipose-Derived Extract Suppresses IL-1β-Induced Inflammatory Signaling Pathways in Human Chondrocytes and Ameliorates the Cartilage Destruction of Experimental Osteoarthritis in Rats. International journal

    Hideki Ohashi, Keiichiro Nishida, Aki Yoshida, Yoshihisa Nasu, Ryuichi Nakahara, Yoshinori Matsumoto, Ayumu Takeshita, Daisuke Kaneda, Masanori Saeki, Toshifumi Ozaki

    International journal of molecular sciences   22 ( 18 )   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We investigated the effects of adipose-derived extract (AE) on cultured chondrocytes and in vivo cartilage destruction. AE was prepared from human adipose tissues using a nonenzymatic approach. Cultured human chondrocytes were stimulated with interleukin-1 beta (IL-1β) with or without different concentrations of AE. The effects of co-treatment with AE on intracellular signaling pathways and their downstream gene and protein expressions were examined using real-time PCR, Western blotting, and immunofluorescence staining. Rat AE prepared from inguinal adipose tissues was intra-articularly delivered to the knee joints of rats with experimental osteoarthritis (OA), and the effect of AE on cartilage destruction was evaluated histologically. In vitro, co-treatment with IL-1β combined with AE reduced activation of the p38 and ERK mitogen-activated protein kinase (MAPK) pathway and nuclear translocation of the p65 subunit of nuclear factor-kappa B (NF-κB), and subsequently downregulated the expressions of matrix metalloproteinase (MMP)-1, MMP-3, MMP-13, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4, IL-6, and IL-8, whereas it markedly upregulated the expression of IL-1 receptor type 2 (IL-1R2) in chondrocytes. Intra-articular injection of homologous AE significantly ameliorated cartilage destruction six weeks postoperatively in the rat OA model. These results suggested that AE may exert a chondroprotective effect, at least in part, through modulation of the IL-1β-induced inflammatory signaling pathway by upregulation of IL-1R2 expression.

    DOI： 10.3390/ijms22189781

    PubMed

    researchmap

  • Corrigendum: RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion (Front. Oncol., (2021), 11, 10.3389/fonc.2021.665273)

    Fang He, Yoshinori Matsumoto, Yosuke Asano, Yuriko Yamamura, Takayuki Katsuyama, Jose La Rose, Nahoko Tomonobu, Ni Luh Gede Yoni Komalasari, Masakiyo Sakaguchi, Robert Rottapel, Jun Wada

    Frontiers in Oncology   11   2021.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Frontiers Media S.A.  

    DOI： 10.3389/fonc.2021.729192

    Scopus

    researchmap

  • Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study International journal

    Yoshia Miyawaki, Sayaka Shimizu, Yusuke Ogawa, Ken-ei Sada, Yu Katayama, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu-Asano, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Mariko Takano-Narazaki, Yoshinori Matsumoto, Nobuyuki Yajima, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Hajime Yamazaki, Yosuke Yamamoto, Jun Wada, Shunichi Fukuhara

    ARTHRITIS RESEARCH & THERAPY   23 ( 1 )   79 - 79   2021.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/s13075-021-02466-2

    Web of Science

    PubMed

    researchmap

  • Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies

    Haruki Watanabe, Ken-Ei Sada, Yoshinori Matsumoto, Masayoshi Harigai, Koichi Amano, Shouichi Fujimoto, Hiroaki Dobashi, Yukio Yuzawa, Kunihiro Yamagata, Eri Muso, Yoshihiro Arimura, Hirofumi Makino, Hitoshi Sugiyama, Seiichi Matsuo, Yoshinari Takasaki, Akihiro Ishizu, Tatsuya Atsumi, Takao Fujii, Yasunori Okada, Sakae Homma, Naotake Tsuboi, Joichi Usui, Shunichi Kumagai, Takahiko Sugihara, Yohko Murakawa, Shogo Banno, Hitoshi Hasegawa, Wako Yumura, Hiroaki Matsubara, Masaharu Yoshida, Kensei Katsuoka, Noriyoshi Ogawa, Atsushi Komatsuda, Satoshi Ito, Atsushi Kawakami, Izaya Nakaya, Takao Saito, Takafumi Ito, Nobuhito Hirawa, Masahiro Yamamura, Masaaki Nakano, Kosaku Nitta, Makoto Ogura, Taio Naniwa, Shoichi Ozaki, Junichi Hirahashi, Tatsuo Hosoya, Takashi Wada, Satoshi Horikoshi, Yasushi Kawaguchi, Taichi Hayashi, Tsuyoshi Watanabe, Daijo Inaguma, Kazuhiko Tsuruya, Noriyuki Homma, Tsutomu Takeuchi, Naoki Nakagawa, Shinichi Takeda, Ritsuko Katafuchi, Masayuki Iwano, Masaki Kobayashi, Hidehiro Yamada

    MODERN RHEUMATOLOGY   31 ( 1 )   205 - 213   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/14397595.2019.1707997

    Web of Science

    researchmap

  • Granulomatosis with polyangiitis with obstructive pneumonia progressing to hypertrophic pachymeningitis A case report International journal

    Keigo Hayashi, Haruki Watanabe, Yuriko Yamamura, Yosuke Asano, Yu Katayama, Sumie Hiramatsu-Asano, Keiji Ohashi, Michiko Morishita, Mariko Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Jun Wada

    MEDICINE   100 ( 3 )   e24028   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/MD.0000000000024028

    Web of Science

    PubMed

    researchmap

  • Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies

    Ken-Ei Sada, Keiji Ohashi, Yosuke Asano, Keigo Hayashi, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Shouichi Fujimoto, Yoshinari Takasaki, Kunihiro Yamagata, Shogo Banno, Hiroaki Dobashi, Koichi Amano, Masayoshi Harigai, Yoshihiro Arimura, Hirofumi Makino

    ARTHRITIS RESEARCH & THERAPY   22 ( 1 )   2020.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/s13075-020-02341-6

    Web of Science

    researchmap

  • Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis International journal

    Keigo Hayashi, Ken-Ei Sada, Yosuke Asano, Sumie Hiramatsu Asano, Yuriko Yamamura, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Mariko Narazaki, Yoshinori Matsumoto, Jun Wada

    SCIENTIFIC REPORTS   10 ( 1 )   18715 - 18715   2020.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-020-75655-9

    Web of Science

    PubMed

    researchmap

  • Risk Factors for Chronic Damage Accumulation Across Different Onset Eras in Systemic Lupus Erythematosus: A Cross-sectional Analysis of a Lupus Registry of Nationwide Institutions (LUNA) Reviewed

    Keiji Ohashi, Ken-Ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu Asano, Yoshia Miyawaki, Michiko Morishita, Eri Katsuyama, Haruki Watanabe, Noriko Tatebe, Mariko Narazaki, Yoshinori Matsumoto, Katsue Sunahori-Watanabe, Tomoko Kawabata, Nobuyuki Yajima, Jun Wada

    ACTA MEDICA OKAYAMA   74 ( 3 )   191 - 198   2020.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

    researchmap

  • Recovery from hypoxemia and Hypercapnia following noninvasive pressure support ventilation in a patient with statin-associated necrotizing myopathy: a case report Reviewed International journal

    Yuriko Yamamura, Yoshinori Matsumoto, Koh Tadokoro, Yasuyuki Ohta, Kota Sato, Toru Yamashita, Masahiro Yamamura, Ken-Ei Sada, Koji Abe, Jun Wada

    BMC PULMONARY MEDICINE   20 ( 1 )   156 - 156   2020.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/s12890-020-01195-7

    Web of Science

    PubMed

    researchmap

  • Association of explanatory histological findings and urinary protein and serum creatinine levels at renal biopsy in lupus nephritis: a cross-sectional study Reviewed International journal

    Eri Katsuyama, Yoshia Miyawaki, Ken-ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu-Asano, Michiko Morishita, Keiji Ohashi, Haruki Watanabe, Takayuki Katsuyama, Mariko Narazaki, Yoshinori Matsumoto, Jun Wada

    BMC NEPHROLOGY   21 ( 1 )   208 - 208   2020.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1186/s12882-020-01868-9

    Web of Science

    PubMed

    researchmap

  • Benzonaseを用いた新規骨芽細胞分離法の開発 Reviewed

    浅野 洋介, 松本 佳則, Ziyi Wang, 佐田 憲映, 上岡 寛, 和田 淳

    日本骨形態計測学会雑誌   30 ( 1 )   S99 - S99   2020.5

    　More details

    Language：Japanese   Publisher：日本骨形態計測学会  

    researchmap

  • Letter to the Editor (Case report)

    Yuriko Yamamura, Yoshinori Matsumoto, Yosuke Asano, Yu Katayama, Keigo Hayashi, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Mariko Takano-Narazaki, Ken-Ei Sada, Jun Wada

    RHEUMATOLOGY ADVANCES IN PRACTICE   4 ( 1 )   2020

    　More details

  • Damage accrual related to pregnancies before and after diagnosis of systemic lupus erythematosus: a cross-sectional and nested case-control analysis from a lupus registry Reviewed

    Michiko Morishita, Ken-Ei Sada, Keiji Ohashi, Yoshia Miyawaki, Yosuke Asano, Keigo Hayashi, Sumie Hiramatsu Asano, Yuriko Yamamura, Haruki Watanabe, Mariko Narazaki, Yoshinori Matsumoto, Tomoko Kawabata, Nobuyuki Yajima, Jun Wada

    Lupus   in press   2019.12

    　More details

  • Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/Dermatomyositis. Reviewed International journal

    Keiji Ohashi, Ken-Ei Sada, Yu Nakai, Shun Matsushima, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Yoshia Miyawaki, Michiko Morishita, Takayuki Katsuyama, Eri Katsuyama, Haruki Watanabe, Noriko Tatebe, Mariko Narazaki, Yoshinori Matsumoto, Katsue Sunahori Watanabe, Tomoko Kawabata, Jun Wada

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases   25 ( 6 )   246 - 251   2019.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. METHODS: Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies. Clinical symptoms and relapse proportions were compared among these clusters. RESULTS: Sixty-one patients were enrolled in this study: 28 were diagnosed with PM, and 33 were diagnosed with DM. The following 3 clusters were determined: 1 (n = 10), anti-Jo-1 and anti-SS-A/Ro-52 antibodies double positive (10/10, 100%); 2 (n = 24), anti-SS-A/Ro-52 antibody positive (20/24, 83%), anti-Jo-1 antibody negative (24/24, 100%), and anti-ARS antibodies (excluding anti-Jo-1 antibody) positive (15/24, 63%); and 3 (n = 27), anti-Jo-1 and anti-SS-A/Ro52 antibodies double negative (26/27, 96%). The proportion of patients who relapsed was significantly lower in cluster 3 than it was in clusters 1 and 2 (risk ratio, 0.37; 95% confidence interval, 0.17-0.83; p = 0.026 and risk ratio, 0.42; 95% confidence interval, 0.20-0.89; P = 0.019, respectively). There was no difference in the proportion of relapsed patients between clusters 1 and 2. CONCLUSIONS: Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.

    DOI： 10.1097/RHU.0000000000000836

    PubMed

    researchmap

  • Development of Hypertrophic Pachymeningitis in a Patient With Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis With Polyangiitis. Reviewed International journal

    Yasuhiro Nakano, Yoshia Miyawaki, Ken-Ei Sada, Yuriko Yamamura, Yuzuki Kano, Keigo Hayashi, Haruki Watanabe, Yoshinori Matsumoto, Tomoko Kawabata, Jun Wada

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases   25 ( 5 )   e61   2019.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/RHU.0000000000000694

    PubMed

    researchmap

  • Thrombocytosis as a prognostic factor in polymyalgia rheumatica: characteristics determined from cluster analysis Reviewed International journal

    Keigo Hayashi, Keiji Ohashi, Haruki Watanabe, Ken-Ei Sada, Kenta Shidahara, Yosuke Asano, Sumie Hiramatsu Asano, Yuriko Yamamura, Yoshia Miyawaki, Michiko Morishita, Yoshinori Matsumoto, Tomoko Kawabata, Jun Wada

    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE   11   1759720X19864822   2019.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1177/1759720X19864822

    Web of Science

    PubMed

    researchmap

  • Regulation of Cathepsin E gene expression by the transcription factor Kaiso in MRL/lpr mice derived CD4+ T cells. Reviewed International journal

    Sumie Hiramatsu, Katsue S Watanabe, Sonia Zeggar, Yosuke Asano, Yoshia Miyawaki, Yuriko Yamamura, Eri Katsuyama, Takayuki Katsuyama, Haruki Watanabe, Mariko Takano-Narazaki, Yoshinori Matsumoto, Tomoko Kawabata, Ken-Ei Sada, Jun Wada

    Scientific reports   9 ( 1 )   3054 - 3054   2019.2

    　More details

    Language：English   Publisher：Springer Nature  

    Global DNA hypomethylation in CD4+ cells in systemic lupus erythematosus (SLE) was suggested to play a key role in the pathogenesis. To identify new methylation-sensitive genes, we integrated genome-wide DNA methylation and mRNA profiling data in CD4+ cells of MRL/lpr (MRL) and C57BL6/J (B6) mice. We identified Cathepsin E (Ctse), in which 13 methyl-CpGs within 583 bp region of intron 1 were hypomethylated, and Ctse mRNA upregulated in MRL compared with B6 mice. One of methyl-CpGs, mCGCG was 93.3 ± 2.05% methylated in B6 mice, while 80.0 ± 6.2% methylated and mutated to CGGG in MRL mice. Kaiso is known to bind to mCGCG and we hypothesized that it represses expression of Ctse in B6 mice. The binding of Kaiso to mCGCG site in B6 mice was reduced in MRL mice revealed by ChIP-PCR. EL4 cells treated with 5-azaC and/or Trichostatin A showed the suppression of binding of Kaiso to mCGCG motif by ChIP-PCR and the overexpression of Ctse was demonstrated by qPCR. Ctse gene silencing by siRNA in EL4 cells resulted in reduction of IL-10 secretion. The hypomethylation of mCGCG motif, reduced recruitment of Kaiso, and increased expression of Ctse and Il-10 in CD4+ cells may be involved in the pathogenesis of SLE.

    DOI： 10.1038/s41598-019-38809-y

    PubMed

    researchmap

  • Lymphoproliferative disease in a patient with Takayasu arteritis and ulcerative colitis Reviewed

    Yosuke Asano, Ken-Ei Sada, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Keiji Ohashi, Yoshia Miyawaki, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Tomoko Kawabata, Noriyuki Tanaka, Sakiko Hiraoka, Jun Wada

    Modern Rheumatology Case Reports   3 ( 1 )   34   2019.1

    　More details

    Publisher：Informa {UK} Limited  

    DOI： 10.1080/24725625.2018.1507271

    researchmap

  • Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Reviewed International journal

    Michiko Morishita, Ken-Ei Sada, Yoshinori Matsumoto, Keigo Hayashi, Yosuke Asano, Sumie Hiramatsu Asano, Keiji Ohashi, Yoshia Miyawaki, Eri Katsuyama, Haruki Watanabe, Tomoko Kawabata, Jun Wada

    PloS one   14 ( 7 )   e0218705   2019

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    AIMS: Cytomegalovirus (CMV) infection under immunosuppression sometimes causes death. This study aimed to elucidate risk factors for CMV infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). METHODS: Patients with AAV who underwent remission induction treatment at Okayama University Hospital between 2006 and 2016 were retrospectively analyzed. The primary outcome was the development of CMV infection within 3 months. RESULTS: Of the 111 patients, 13 (11.7%) patients developed CMV infection. Patients with CMV infection were older (p = 0.030) and had a higher body mass index (p = 0.029) in comparison to those without CMV infection. A higher proportion had a severe form (p = 0.001) and granulomatosis with polyangiitis (GPA) (p = 0.001), as well as a higher Birmingham Vasculitis Activity Score (p = 0.018) and C-reactive protein (p = 0.018) levels at baseline. Using logistic regression analysis, severe form and GPA were independent risk factors (odds ratio [OR] = 9.68, 95% confidence interval [CI] = 1.92-60.23, and OR = 7.46, 95% CI = 1.46-47.60, respectively). In addition, patients with CMV infection were more likely than those without infection to be glucocorticoid-related diabetes mellitus (p = 0.025). CONCLUSION: Our study highlights disease severity and subgroups of AAV as risk factors for CMV infection.

    DOI： 10.1371/journal.pone.0218705

    PubMed

    researchmap

  • Antineutrophil cytoplasmic antibody-positive familial Mediterranean fever and hyperthyroidism: A case report. International journal

    Sorato Segoe, Ken-Ei Sada, Keigo Hayashi, Yuriko Yamamura, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Jun Wada

    Medicine   97 ( 51 )   e13805   2018.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    RATIONALE: Familial Mediterranean fever (FMF) is a genetic autoinflammatory disorder characterized by serositis and recurrent fever. Previous reports identified patients with antineutrophil cytoplasmic antibody (ANCA)-positive FMF, but vasculitis symptoms were not reported. PATIENT CONCERNS: We report the case of a 44-year-old man with numbness. He had a history of 3 episodes of pleurisy and was being treated with propylthiouracil for hyperthyroidism. Because he was ANCA-positive, we suspected drug-induced ANCA-associated vasculitis and propylthiouracil was discontinued. However, his numbness was not ameliorated, and he again developed high fever with pleurisy. DIAGNOSIS: Diagnosis of FMF was finally made, and genetic analysis revealed compound heterozygous mutations in exon 2 of the familial Mediterranean fever gene (L110P/E148Q). INTERVENTIONS: The patient was treated with 0.5 mg/day of colchicine. OUTCOMES: His numbness improved, and fever has not recurred. LESSONS: Appearance of ANCA and development of vasculitis should be considered in a clinical course of FMF with hyperthyroidism.

    DOI： 10.1097/MD.0000000000013805

    PubMed

    researchmap

  • Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus Reviewed

    Y Miyawaki, K Sada, Y Asano, K Hayashi, Y Yamamura, S Hiramatsu, K Ohashi, M Morishita, H Watanabe, Y Matsumoto, T Kawabata, J Wada

    Lupus   27 ( 13 )   2093   2018.11

    　More details

    Publisher：{SAGE} Publications  

    DOI： 10.1177/0961203318804892

    researchmap

  • An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin. Reviewed International journal

    Yoshia Miyawaki, Ken-Ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Katsue Sunahori-Watanabe, Tomoko Kawabata, Jun Wada

    Journal of medical case reports   12 ( 1 )   288 - 288   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of glucocorticoid-induced diabetes mellitus. METHODS: From December 2014 to November 2015, we recruited non-diabetic Japanese patients scheduled for treatment with daily prednisolone ≥20 mg. Enrolled patients had at least one of following risk factors for glucocorticoid-induced diabetes mellitus: estimated glomerular filtration rate ≤ 60 mL/minute/1.73 m2; age ≥ 65 years; hemoglobin A1c > 6.0%. A daily dose of 5 mg of linagliptin was administered simultaneously with glucocorticoid therapy. The primary outcome was the development of glucocorticoid-induced diabetes mellitus. Additional orally administered hypoglycemic medications and/or insulin injection therapy was initiated according to the blood glucose level. RESULTS: Four of five patients developed glucocorticoid-induced diabetes mellitus within 1 week of glucocorticoid treatment. For 12 weeks, two of the four patients with glucocorticoid-induced diabetes mellitus required orally administered medications, but no patients required insulin. Blood glucose levels before breakfast and lunch tended to decrease with time; the median glucose levels before breakfast were 93 and 79.5 mg/dL at 1 and 3 weeks, respectively. Two patients experienced mild hypoglycemia around 2 weeks. Glucose levels after lunch remained high throughout all 4 weeks despite decreasing the glucocorticoid dosage. CONCLUSIONS: Linagliptin may be insufficient to prevent the development of glucocorticoid-induced diabetes mellitus but has the potential to reduce the requirement for insulin injection therapy. Treatment of glucocorticoid-induced diabetes mellitus was continued for at least 1 month and fasting hypoglycemia in early morning should be monitored after 2 weeks. TRIAL REGISTRATION: This trial was registered 02 November 2014 with UMIN Clinical Trials Registry (no. 000015588 ).

    DOI： 10.1186/s13256-018-1817-6

    PubMed

    researchmap

  • Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies. Reviewed International journal

    Watanabe H, Sada KE, Matsumoto Y, Harigai M, Amano K, Dobashi H, Fujimoto S, Usui J, Yamagata K, Atsumi T, Banno S, Sugihara T, Arimura Y, Matsuo S, Makino H, Japan Research Committee of, the, Ministry of Health,Labour, d Welfare for Intractable Vasculitis, the Research Committee of, Intractable Renal, Disease of, the, Ministry of Health,Labour, Welfare of Japan

    Arthritis & rheumatology (Hoboken, N.J.)   70 ( 10 )   1626 - 1633   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: To evaluate clinical links between levels of myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) and relapse in patients with ANCA-associated vasculitis (AAV) using a data set from 2 nationwide prospective cohort studies. METHODS: From the cohort studies, MPO-ANCA-positive patients who achieved remission during the 6 months after remission induction therapy were enrolled. We measured MPO-ANCA levels at months 0, 3, 6, 12, 18, 24, and at the time of relapse. The primary outcome measure was relapse. A nested case-control analysis and multivariable analysis were performed to investigate the relationship between ANCA reappearance and relapse. RESULTS: Of 271 patients, 183 were classified as having microscopic polyangiitis, 34 as having granulomatosis with polyangiitis, 15 as having eosinophilic granulomatosis with polyangiitis, and 39 were unclassifiable. The median age was 73 years, and 165 (61%) were female. In 195 patients (72%), MPO-ANCA levels decreased to normal levels within 6 months after commencement of treatment, and MPO-ANCA reappeared in 73 of 181 patients (40%) with complete follow-up data. Reappearance of MPO-ANCA was more frequent in patients with relapse than in 75 age- and sex-matched control patients without relapse (odds ratio 26.2 [95% confidence interval 8.2-101], P < 0.0001) after adjustment for confounding factors. CONCLUSION: Reappearance of MPO-ANCA could be a clinically useful biomarker for predicting relapse in patients with MPO-ANCA-positive AAV in remission. This suggests that routine MPO-ANCA monitoring should be implemented in this patient population.

    DOI： 10.1002/art.40538

    PubMed

    researchmap

  • Hemoptysis Originating from the Bronchial Artery in Takayasu Arteritis with Ulcerative Colitis. Reviewed

    Imamura R, Hayashi K, Sada KE, Yamamura Y, Yamaguchi S, Morishita M, Watanabe H, Matsumoto Y, Wada J

    Internal medicine (Tokyo, Japan)   58 ( 2 )   293 - 295   2018.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Takayasu arteritis (TAK) is a large-vessel vasculitis affecting the aorta and its main branches. Hemoptysis can be experienced as the respiratory manifestation, but origination from a bronchial artery is rare. Ulcerative colitis (UC) shares genetic similarities with TAK; HLA-B52*01 is associated with TAK and UC. We herein report a patient who presented with hemoptysis from the right bronchial artery and was diagnosed with TAK during the follow-up of UC. Transcatheter embolization was performed, and prednisolone and tocilizumab induced remission. Complication of TAK should be considered in the clinical course of HLA-B52-positive UC patients, and tocilizumab may be a treatment option.

    DOI： 10.2169/internalmedicine.1463-18

    PubMed

    researchmap

  • Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab Reviewed

    K. Shidahara, K. Hayashi, K. E. Sada, S. Hiramatsu, M. Morishita, H. Watanabe, Y. Matsumoto, T. Kawabata, J. Wada

    Lupus   27 ( 8 )   1374 - 1377   2018.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：SAGE Publications Ltd  

    DOI： 10.1177/0961203318760994

    Scopus

    researchmap

  • Role of Lgals9 Deficiency in Attenuating Nephritis and Arthritis in BALB/c Mice in a Pristane-Induced Lupus Model Reviewed International journal

    Sonia Zeggar, Katsue S. Watanabe, Sanae Teshigawara, Sumie Hiramatsu, Takayuki Katsuyama, Eri Katsuyama, Haruki Watanabe, Yoshinori Matsumoto, Tomoko Kawabata, Ken-ei Sada, Toshiro Niki, Mitsuomi Hirashima, Jun Wada

    ARTHRITIS & RHEUMATOLOGY   70 ( 7 )   1089 - 1101   2018.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/art.40467

    Web of Science

    PubMed

    researchmap

  • Cavernous Transformation and Granulomatous Epididymis in Behçet Disease. Reviewed International journal

    Motokura Y, Watanabe H, Yamamura Y, Kano Y, Matsumoto Y, Kawabata T, Sada KE, Wada J

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases   25 ( 4 )   45 - 47   2018.2

    　More details

  • Regulatory effects of fibroblast growth factor-8 and tumor necrosis factor-alpha on osteoblast marker expression induced by bone morphogenetic protein-2 Reviewed

    Takayuki Katsuyama, Fumio Otsuka, Tomohiro Terasaka, Kenichi Inagaki, Mariko Takano-Narazaki, Yoshinori Matsumoto, Ken-Ei Sada, Hirofumi Makino

    PEPTIDES   73   88 - 94   2015.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.peptides.2015.09.007

    Web of Science

    PubMed

    researchmap

  • Enhanced expression of bone morphogenetic protein system in aldosterone-treated mouse kidneys Reviewed

    Jiro Suzuki, Fumio Otsuka, Yoshinori Matsumoto, Kenichi Inagaki, Tomoko Miyoshi, Masaya Takeda, Naoko Tsukamoto, Eri Nakamura, Kanako Ogura, Hirofumi Makino

    HYPERTENSION RESEARCH   35 ( 3 )   312 - 317   2012.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/hr.2011.186

    Web of Science

    PubMed

    researchmap

  • Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-alpha Reviewed

    Mariko Takano, Fumio Otsuka, Yoshinori Matsumoto, Kenichi Inagaki, Masaya Takeda, Eri Nakamura, Naoko Tsukamoto, Tomoko Miyoshi, Ken-ei Sada, Hirofumi Makino

    MOLECULAR AND CELLULAR ENDOCRINOLOGY   348 ( 1 )   224 - 232   2012.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.mce.2011.08.027

    Web of Science

    PubMed

    researchmap

  • Mutual Regulation of Growth Hormone and Bone Morphogenetic Protein System in Steroidogenesis by Rat Granulosa Cells Reviewed

    Eri Nakamura, Fumio Otsuka, Kenichi Inagaki, Tomoko Miyoshi, Yoshinori Matsumoto, Kanako Ogura, Naoko Tsukamoto, Masaya Takeda, Hirofumi Makino

    ENDOCRINOLOGY   153 ( 1 )   469 - 480   2012.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1210/en.2011-1646

    Web of Science

    PubMed

    researchmap

  • Functional interaction of fibroblast growth factor-8, bone morphogenetic protein and estrogen receptor in breast cancer cell proliferation Reviewed

    Hiroko Masuda, Fumio Otsuka, Yoshinori Matsumoto, Mariko Takano, Tomoko Miyoshi, Kenichi Inagaki, Tadahiko Shien, Naruto Taira, Hirofumi Makino, Hiroyoshi Doihara

    MOLECULAR AND CELLULAR ENDOCRINOLOGY   343 ( 1-2 )   7 - 17   2011.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.mce.2011.05.037

    Web of Science

    PubMed

    researchmap

  • Unexpected occurrence of adrenal Cushing&apos;s syndrome in a patient with systemic lupus erythematosus Reviewed

    Akihiro Katayama, Fumio Otsuka, Katsuyuki Tanabe, Naoko Tsukamoto, Ryutaro Yamanaka, Yoshinori Matsumoto, Yasutomo Nasu, Hirofumi Makino

    HYPERTENSION RESEARCH   34 ( 5 )   662 - 663   2011.5

    　More details

  • ステロイドによる骨芽細胞分化および炎症性骨分化抑制への影響

    松本 佳則, 大塚 文男, 高野 真理子, 向井 知之, 武田 昌也, 三好 智子, 稲垣 兼一, 槇野 博史

    日本内分泌学会雑誌   86 ( 2 )   408 - 408   2010.9

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

  • Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling Reviewed

    Misuzu Yamashita, Fumio Otsuka, Tomoyuki Mukai, Ryutaro Yamanaka, Hiroyuki Otani, Yoshinori Matsumoto, Eri Nakamura, Mariko Takano, Ken-ei Sada, Hirofumi Makino

    REGULATORY PEPTIDES   162 ( 1-3 )   99 - 108   2010.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.regpep.2010.03.003

    Web of Science

    PubMed

    researchmap

  • Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension Reviewed

    Ryutaro Yamanaka, Fumio Otsuka, Kazufumi Nakamura, Misuzu Yamashita, Hiroyuki Otani, Masaya Takeda, Yoshinori Matsumoto, Kengo F. Kusano, Hiroshi Ito, Hirofumi Makino

    HYPERTENSION RESEARCH   33 ( 5 )   435 - 445   2010.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/hr.2010.16

    Web of Science

    PubMed

    researchmap

▼display all

Books

  • ANCA関連血管炎の分子標的

    松本佳則他

    Bio Clinica  2024 

    　More details

  • 移植後骨粗鬆症（最新の骨粗鬆症学）

    松本佳則他

    日本臨床  2023.1 

    　More details

  • タンキレースはTLR2シグナルの減弱を介し自己炎症を抑制する

    松本佳則

    リウマチ科（科学評論社）  2023 

    　More details

  • ACR/VFによるAAV診療ガイドライン（ANCA関連血管炎臨床ガイドライン2023）

    松本佳則他

    診断と治療社  2023 

    　More details

  • 好酸球性多発血管炎性肉芽腫症

    松本佳則

    岡山医学会雑誌  2022.8 

    　More details

  • 関節リウマチ治療実践バイブル（改訂第2版）

    松本佳則（VI 薬物療法の副作用対策-3．csDMARD：免疫調節薬）

    南江堂  2022.5 

    　More details

  • リウマチ病学テキスト改訂第3版

    松本佳則（メトトレキサート）

    南江堂  2022.5 

    　More details

  • Rituximabによる顕微鏡的多発血管炎/多発血管炎性肉芽腫症の治療

    松本佳則

    リウマチ科（科学評論社）  2022.2 

    　More details

  • 難治性ネフローゼ症候群に対するリツキシマブ

    中土井崇人 松本佳則

    リウマチ科（科学評論社）  2022 

    　More details

  • ANCA関連血管炎診療の新展開

    松本佳則

    日本内科学会雑誌  2021 

    　More details

  • Benzonaseを用いた新規骨芽細胞分離法の開発

    浅野洋介, 松本佳則

    日本骨形態計測学会誌  2020.5 

    　More details

  • 話題：ループス腎炎の尿細管細胞とケラチノサイトのシングルセル解析による Ⅰ型インターフェロンと線維化パスウェイの同定

    松本佳則

    リウマチ科  2020 

    　More details

  • 話題：JAK阻害薬による血管炎治療の可能性

    内田治仁, 松本佳則

    リウマチ科  2019 

    　More details

  • 話題：新規TNFアッセイ法によるアダリムマブ治療中の循環TNFの動態

    松本佳則

    リウマチ科  2019 

    　More details

  • 話題：炎症強度依存性の骨誘導性Wnt蛋白が強直性脊椎炎における異所性骨形成に必須である

    松本佳則

    リウマチ科  2018 

    　More details

  • 全身性血管炎による腎病変

    松本佳則, 佐田憲映

    リウマチ科  2018 

    　More details

  • 顕微鏡的多発血管炎

    松本佳則, 佐田憲映

    医学のあゆみ  2011 

    　More details

  • ANCA関連血管炎研究の最近の進歩

    松本佳則, 佐田憲映, 槇野博史

    医学のあゆみ  2010 

    　More details

▼display all

MISC

  • THE MINIMALLY IMPORTANT DIFFERENCE AS THE INTERPRETABILITY OF EMOTIONAL HEALTH DOMAIN IN JAPANESE VERSION OF LupusPRO FOR SLE PATIENTS; PRELIMINARY RESULTS OF A PROSPECTIVE COHORT STUDY Reviewed

    Y. Miyawaki, K. Shidahara, S. Nawachi, Y. Asano, Y. Katayama, K. Ohashi, E. Katsuyama, T. Katsuyama, M. Narazaki, Y. Matsumoto, K. E. Sada, R. Yanai, N. Yajima, A. Takatani, K. Ichinose, J. Wada

    Annals of the Rheumatic Diseases   81 ( Suppl 1 )   1083.2 - 1084   2022.6

    　More details

    Publisher：BMJ  

    Background

    The minimally important difference (MID) required to interpret the magnitude of changes in lupus patient-reported outcome (LupusPRO), which is a widely used outcome measure of quality of life in SLE patients, remains unclear.

    Objectives

    We report preliminary results of an ongoing prospective observational study that assesses the MID as the interpretability of emotional health (EH) domain in Japanese version of LupusPRO.

    Methods

    We recruited subjects at three university hospitals in Japan participating in an ongoing multidisciplinary cohort study (the Lupus registry of Nationwide institutions (LUNA). Of a total of 210 SLE patients enrolled during the 17-month recruitment period, patients with low disease activity, defined as SLE Disease Activity Index 2000 (SLEDAI-2K) ≤ 4, and who were seen at least twice of three months’ duration and responded to both the LupusPRO and health status change questions were included in this subcohort. The second questionnaire was given an allowance period of 30 days before or after the ​three months from starting date. Descriptive statistics were presented as means and standard deviations (SD) or counts and percentages (%). The emotional health score ranges from 0 to 100; a higher score indicates less frequent presence of symptoms. The change in health status was assessed using the 7-point Global Rating of Change 1), and the score = 0 and the score ≥ +1 were considered in the ‘unchanged’ and the minimal ‘improved’ category, respectively. MID was mainly estimated using the mean change of the groups with the score ≥ +1 as the anchor-based method, and the area under the curve (AUC) was also calculated as a sensitivity analysis to estimate MID thresholds 2) and 95% confidence intervals (CI) were constructed using 1000 bootstrapping.

    Results

    The mean age of the 24 eligible patients was 48 (SD 14), and 88% were female. The glucocorticoid dose, SLEDAI-2K, and Systemic Lupus International Collaborating Clinics /American College of Rheumatology Damage Index were 3.4 (2.1) mg, 1.0 (1.1) and 1.1 (1.9), respectively. The mean EH score was 67.5 (30.3), five patients (21%) had the maximum EH score at baseline, 73.4 (25.0) after three months, 7.2 (18.0) for the change in EH. The correlation coefficient and the AUC for the change in health status and the EH were 0.23 and 0.60. The mean changes were 4.1 (18.4) of the groups with ‘unchanged’ health status and 12.3 (17.1) of the groups with ‘improved’ health status. The MID for improvement was estimated at 12.3 using the anchor-based method, and the cutoff point corresponded to 9.3 [95%CI -6.7 to 25.3]) of the EH change score by the receiver operating curve method.

    Conclusion

    In this study, the MID (3 months) for the EH domain in the Japanese version of LupusPRO was estimated to be between 9 and 12, which was similar to the results of the previous cross-sectional study 3). The challenge in estimating the MID in our setting was the low correlation with external anchors, even though the study population was limited to patients with low disease activity, because disease activity at baseline can generally influence ‘improved’ health status.

    References

    [1]Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163.

    [2]Froud R, Abel G. Using ROC curves to choose minimally important change thresholds when sensitivity and specificity are valued equally: the forgotten lesson of pythagoras. theoretical considerations and an example application of change in health status. PLoS One. 2014;9(12):e114468.

    [3]Miyawaki Y, Shimizu S, Ogawa Y, et al. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study. Arthritis Res Ther. 2021;23(1):79.

    Acknowledgements

    The authors thank Yuka Nakanou for her significant assistance in data management and Kikuko Miyazaki for her expert assistance on this topic.

    Disclosure of Interests

    Yoshia Miyawaki: None declared, Kenta Shidahara: None declared, Shoichi Nawachi: None declared, Yosuke ASANO: None declared, Yu Katayama: None declared, Keiji Ohashi: None declared, Eri Katsuyama: None declared, Takayuki Katsuyama: None declared, Mariko Narazaki: None declared, Yoshinori Matsumoto Speakers bureau: I received speaker’s fees from Glaxo Smith Kline K.K., KEN-EI SADA Speakers bureau: I received speaker’s fees from Glaxo Smith Kline K.K., Ryo Yanai: None declared, Nobuyuki Yajima: None declared, Ayuko Takatani: None declared, Kunihiro Ichinose: None declared, Jun Wada Speakers bureau: Jun Wada receives speaker honoraria from Astra Zeneca, Daiichi Sankyo, Novartis, Novo Nordisk Pharma, Tanabe Mitsubishi and receives grant support from Astellas, Baxter, Bayer, Chugai, Dainippon Sumitomo, Kyowa Kirin, Novo Nordisk Pharma, Ono, Otsuka, Tanabe Mitsubishi, and Teijin.

    DOI： 10.1136/annrheumdis-2022-eular.1406

    researchmap

  • SLEにおける疾患活動性とQOL 全身性エリテマトーデス診療における医師の性格特性と治療目標達成との関連 TRUMP2-SLE研究

    佐田 憲映, 宮脇 義亜, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 大橋 敬司, 勝山 隆行, 勝山 恵理, 楢崎 真理子, 松本 佳則, 小黒 奈緒, 矢嶋 宣幸, 吉見 竜介, 下島 恭弘, 栗田 宜明

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   367 - 367   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • SLEにおける疾患活動性とQOL SLE患者の健康関連QOL指標の解釈を可能にする最小重要差の検討 前向きコホート研究から登録時記述疫学

    松本 和也, 宮脇 義亜, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 大橋 敬司, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 柳井 亮, 矢嶋 宣幸, 高谷 亜由子, 一瀬 邦弘, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   367 - 367   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 大型血管炎が疑われた大動脈周囲悪性リンパ腫の1例

    道廣 麻友, 勝山 隆行, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 楢崎 真理子, 佐田 憲映, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   756 - 756   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 初発から40年後に診断に至った炎症症候持続TNF受容体関連周期性症候群の一例

    高嶋 香菜子, 松本 佳則, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   756 - 756   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 痛風性関節炎、特発性間質性肺炎発症後に多発脳梗塞を呈した顕微鏡的多発血管炎(MPA)の1例

    堀口 裕紀, 松本 佳則, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   756 - 756   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 横隔膜挙上に伴う呼吸困難を合併した巨細胞性動脈炎(GCA)の一例

    松岡 雅人, 松本 佳則, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   755 - 755   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 動眼神経麻痺を発症した巨細胞性動脈炎の一例

    清水 崇司, 勝山 隆行, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 楢崎 真理子, 佐田 憲映, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   755 - 755   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 爪形成不全と肘関節脱臼を伴った関節リウマチの1例

    増田 倫敦, 松本 佳則, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   754 - 754   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • IgG4関連肥厚性硬膜炎に重篤な視力障害を来たし視神経周囲炎が示唆された一例

    上舞 直, 宮脇 義亜, 松本 和也, 中土井 崇人, 大橋 敬司, 廣瀬 啓, 縄稚 翔一, 志田原 健太, 浅野 洋介, 片山 祐, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   754 - 754   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 高安動脈炎が疑われたがPET-CTを契機に希少疾患であるシトステロール血症と判明した一例

    中土井 崇人, 勝山 恵理, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 宮脇 義亜, 大橋 敬司, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   672 - 672   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • COVID-19ワクチン接種後に脊椎関節炎が顕在化した一例

    志田原 健太, 松本 佳則, 松本 和也, 廣瀬 啓, 中土井 崇人, 縄稚 翔一, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   627 - 627   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 臨床(内科)・症例報告 大学病院に勤務する膠原病・リウマチ内科医のバーンアウト(燃え尽き症候群)とグリットとの関連 TRUMP2-SLE研究

    宮脇 義亜, 佐田 憲映, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 大橋 敬司, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 小黒 奈緒, 矢嶋 宣幸, 吉見 竜介, 下島 恭弘, 和田 淳, 栗田 宜明

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   435 - 435   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • リウマチ性疾患におけるCOVID-19感染症 COVID-19肺炎後に器質化肺炎(OP)を合併した関節リウマチ(RA)の1例

    吉永 泰彦, 相田 哲史, 西山 進, 宮脇 昌二, 大橋 敬司, 宮脇 義亜, 松本 佳則

    日本リウマチ学会総会・学術集会プログラム・抄録集   66回   395 - 395   2022.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 胸膜炎を合併したシェーグレン症候群の一例

    大武 春香, 勝山 隆行, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 松本 佳則, 楢崎 真理子, 佐田 憲映, 大塚 文男, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   65回   724 - 724   2021.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 大動脈周囲に軟部腫瘤影を認めた多発血管炎性肉芽腫症(GPA)の一例

    末長 理恵, 松本 佳則, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   65回   724 - 724   2021.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 二度の急性心筋梗塞を発症した血管ベーチェットの一例

    アサモア・アビ, 勝山 隆行, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 松本 佳則, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   65回   724 - 724   2021.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 多発性筋炎、間質性肺炎治療中に前腕腫脹で判明した転移性結核膿瘍の1例

    上里 祐賀, 松本 佳則, 縄稚 翔一, 大橋 敬司, 志田原 健太, 浅野 洋介, 片山 祐, 林 啓悟, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   65回   722 - 722   2021.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • ぎりぎりのタイミングで免疫抑制療法を回避できたMPO-ANCA高値不明熱の一例

    昆 尭明, 松本 佳則, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   65回   722 - 722   2021.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • リウマチ性多発筋痛症(PMR)様の症状を呈した急性リンパ性白血病の1例

    縄稚 翔一, 松本 佳則, 志田原 健太, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   65回   709 - 709   2021.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 無筋症候性皮膚筋炎治療中に発症した播種性ノカルジア症の一例

    中土井 崇人, 宮脇 義亜, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 森下 美智子, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   65回   702 - 702   2021.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 関節リウマチに対しインフリキシマブバイオシミラー製剤を導入後にループス腎炎が生じた一例

    志田原 健太, 勝山 隆行, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   65回   579 - 579   2021.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • A case of an 18-year-old man who was diagnosed with subcutaneous panniculitis-like T-cell lymphoma

    和田嵩平, 和田嵩平, 和田嵩平, 勝山隆行, 縄稚翔一, 吉田遥, 松本佳則, 三宅智子, 野村隼人, 中井友美, 山崎江利子, 西森久和, 大山矩史, 谷口恒平, 吉野正, 前田嘉信, 森実真, 和田淳

    日本プライマリ・ケア連合学会学術大会(Web)   12th   np444 - np444   2021

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 全身性エリテマトーデスの慢性損傷に対するビタミンD補給の効果 Lupus registry of Nationwide institutions(LUNA)からの横断分析(Effect of vitamin D supplementation of chronic damage in systemic lupus erythematosus: cross-sectional analysis from a lupus registry of nationwide institutions(LUNA))

    Hayashi Keigo, Sada Ken-ei, Asano Yosuke, Katayama Yu, Ohashi Keiji, Morishita Michiko, Watanabe Haruki, Matsumoto Yoshinori, Yajima Nobuyuki, Yoshimi Ryusuke, Shimojima Yasuhiro, Ohno Shigeru, Kajiyama Hiroshi, Ichinose Kunihiro, Sato Shuzo, Fujiwara Michio, Wada Jun

    日本リウマチ学会総会・学術集会プログラム・抄録集   64回   535 - 535   2020.8

    　More details

    Language：English   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 関節リウマチ患者に多発性肺結節を認めた一例

    山村 裕理子, 川畑 智子, 浅野 洋介, 林 啓悟, 平松 澄恵, 森下 美智子, 大橋 敬司, 渡辺 晴樹, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    岡山医学会雑誌   130 ( 3 )   185 - 185   2018.12

    　More details

    Language：Japanese   Publisher：岡山医学会  

    researchmap

  • 炎症性腸疾患関連関節炎の二次無効にアダリムマブ増量が有効であった2症例

    坂本 萌, 松本 佳則, 浅野 洋介, 林 啓悟, 山村 裕理子, 平松 澄恵, 森下 美智子, 大橋 敬司, 宮脇 義亜, 渡辺 晴樹, 川畑 智子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   62回   856 - 856   2018.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • SLE・抗リン脂質抗体症候群1 全身性エリテマトーデスの妊娠と慢性障害に関する検討

    森下 美智子, 大橋 敬司, 宮脇 義亜, 佐田 憲映, 浅野 洋介, 林 啓悟, 平松 澄恵, 山村 裕理子, 勝山 恵理, 勝山 隆行, 渡辺 晴樹, 楢崎 真理子, 建部 智子, 松本 佳則, 渡部 克枝, 川畑 智子, 矢嶋 宣幸, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   62回   444 - 444   2018.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 門脈海綿状変化と肉芽腫性精巣上体炎を認めたベーチェット病の一例

    本倉 優美, 渡辺 晴樹, 山村 裕理子, 加納 弓月, 浅野 洋介, 林 啓悟, 平松 澄恵, 大橋 敬司, 宮脇 義亜, 森下 美智子, 雛元 紀和, 建部 智子, 松本 佳則, 川畑 智子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   62回   860 - 860   2018.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 抗MDA5抗体が病勢の指標となったclinically amyopathic dermatomyositisの一例

    今村 竜太, 渡辺 晴樹, 山村 裕理子, 浅野 洋介, 林 啓悟, 平松 澄恵, 大橋 敬司, 宮脇 義亜, 森下 美智子, 雛元 紀和, 建部 智子, 松本 佳則, 川畑 智子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集   62回   858 - 858   2018.3

    　More details

    Language：Japanese   Publisher：(一社)日本リウマチ学会  

    researchmap

  • 骨芽細胞分化に対するBMPとERの相互作用の検討

    大塚 文男, 楢崎 真理子, 勝山 隆行, 松本 佳則, 越智 可奈子, 当真 貴志雄, 中村 絵里, 塚本 尚子, 三好 智子, 稲垣 兼一, 小倉 俊郎, 槇野 博史

    日本内分泌学会雑誌   89 ( 1 )   276 - 276   2013.4

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    J-GLOBAL

    researchmap

  • FGF-8とEstrogenによる乳癌細胞の増殖機転とBMPの関与

    増田 紘子, 大塚 文男, 三好 智子, 山中 龍太郎, 高野 真理子, 松本 佳則, 稲垣 兼一, 平 成人, 槇野 博史, 土井原 博義

    日本内分泌学会雑誌   87 ( 1 )   357 - 357   2011.4

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

▼display all

Presentations

  • THE MINIMALLY IMPORTANT DIFFERENCE AS THE INTERPRETABILITY OF EMOTIONAL HEALTH DOMAIN IN JAPANESE VERSION OF LupusPRO FOR SLE PATIENTS; PRELIMINARY RESULTS OF A PROSPECTIVE COHORT STUDY

    Y. Miyawaki, K. Shidahara, S. Nawachi, Y. Asano, Y. Katayama, K. Ohashi, E. Katsuyama, T. Katsuyama, M. Narazaki, Y. Matsumoto, K. E. Sada, R. Yanai, N. Yajima, A. Takatani, K. Ichinose, J. Wada

    Annals of the Rheumatic Diseases  2022.6  BMJ

    　More details

    Event date： 2022.6

    Background

    The minimally important difference (MID) required to interpret the magnitude of changes in lupus patient-reported outcome (LupusPRO), which is a widely used outcome measure of quality of life in SLE patients, remains unclear.

    Objectives

    We report preliminary results of an ongoing prospective observational study that assesses the MID as the interpretability of emotional health (EH) domain in Japanese version of LupusPRO.

    Methods

    We recruited subjects at three university hospitals in Japan participating in an ongoing multidisciplinary cohort study (the Lupus registry of Nationwide institutions (LUNA). Of a total of 210 SLE patients enrolled during the 17-month recruitment period, patients with low disease activity, defined as SLE Disease Activity Index 2000 (SLEDAI-2K) ≤ 4, and who were seen at least twice of three months’ duration and responded to both the LupusPRO and health status change questions were included in this subcohort. The second questionnaire was given an allowance period of 30 days before or after the ​three months from starting date. Descriptive statistics were presented as means and standard deviations (SD) or counts and percentages (%). The emotional health score ranges from 0 to 100; a higher score indicates less frequent presence of symptoms. The change in health status was assessed using the 7-point Global Rating of Change 1), and the score = 0 and the score ≥ +1 were considered in the ‘unchanged’ and the minimal ‘improved’ category, respectively. MID was mainly estimated using the mean change of the groups with the score ≥ +1 as the anchor-based method, and the area under the curve (AUC) was also calculated as a sensitivity analysis to estimate MID thresholds 2) and 95% confidence intervals (CI) were constructed using 1000 bootstrapping.

    Results

    The mean age of the 24 eligible patients was 48 (SD 14), and 88% were female. The glucocorticoid dose, SLEDAI-2K, and Systemic Lupus International Collaborating Clinics /American College of Rheumatology Damage Index were 3.4 (2.1) mg, 1.0 (1.1) and 1.1 (1.9), respectively. The mean EH score was 67.5 (30.3), five patients (21%) had the maximum EH score at baseline, 73.4 (25.0) after three months, 7.2 (18.0) for the change in EH. The correlation coefficient and the AUC for the change in health status and the EH were 0.23 and 0.60. The mean changes were 4.1 (18.4) of the groups with ‘unchanged’ health status and 12.3 (17.1) of the groups with ‘improved’ health status. The MID for improvement was estimated at 12.3 using the anchor-based method, and the cutoff point corresponded to 9.3 [95%CI -6.7 to 25.3]) of the EH change score by the receiver operating curve method.

    Conclusion

    In this study, the MID (3 months) for the EH domain in the Japanese version of LupusPRO was estimated to be between 9 and 12, which was similar to the results of the previous cross-sectional study 3). The challenge in estimating the MID in our setting was the low correlation with external anchors, even though the study population was limited to patients with low disease activity, because disease activity at baseline can generally influence ‘improved’ health status.

    References

    [1]Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163.

    [2]Froud R, Abel G. Using ROC curves to choose minimally important change thresholds when sensitivity and specificity are valued equally: the forgotten lesson of pythagoras. theoretical considerations and an example application of change in health status. PLoS One. 2014;9(12):e114468.

    [3]Miyawaki Y, Shimizu S, Ogawa Y, et al. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study. Arthritis Res Ther. 2021;23(1):79.

    Acknowledgements

    The authors thank Yuka Nakanou for her significant assistance in data management and Kikuko Miyazaki for her expert assistance on this topic.

    Disclosure of Interests

    Yoshia Miyawaki: None declared, Kenta Shidahara: None declared, Shoichi Nawachi: None declared, Yosuke ASANO: None declared, Yu Katayama: None declared, Keiji Ohashi: None declared, Eri Katsuyama: None declared, Takayuki Katsuyama: None declared, Mariko Narazaki: None declared, Yoshinori Matsumoto Speakers bureau: I received speaker’s fees from Glaxo Smith Kline K.K., KEN-EI SADA Speakers bureau: I received speaker’s fees from Glaxo Smith Kline K.K., Ryo Yanai: None declared, Nobuyuki Yajima: None declared, Ayuko Takatani: None declared, Kunihiro Ichinose: None declared, Jun Wada Speakers bureau: Jun Wada receives speaker honoraria from Astra Zeneca, Daiichi Sankyo, Novartis, Novo Nordisk Pharma, Tanabe Mitsubishi and receives grant support from Astellas, Baxter, Bayer, Chugai, Dainippon Sumitomo, Kyowa Kirin, Novo Nordisk Pharma, Ono, Otsuka, Tanabe Mitsubishi, and Teijin.

    researchmap

  • IgG4関連肥厚性硬膜炎に重篤な視力障害を来たし視神経周囲炎が示唆された一例

    上舞 直, 宮脇 義亜, 松本 和也, 中土井 崇人, 大橋 敬司, 廣瀬 啓, 縄稚 翔一, 志田原 健太, 浅野 洋介, 片山 祐, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • SLEにおける疾患活動性とQOL SLE患者の健康関連QOL指標の解釈を可能にする最小重要差の検討 前向きコホート研究から登録時記述疫学

    松本 和也, 宮脇 義亜, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 大橋 敬司, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 柳井 亮, 矢嶋 宣幸, 高谷 亜由子, 一瀬 邦弘, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • リウマチ性疾患におけるCOVID-19感染症 COVID-19肺炎後に器質化肺炎(OP)を合併した関節リウマチ(RA)の1例

    吉永 泰彦, 相田 哲史, 西山 進, 宮脇 昌二, 大橋 敬司, 宮脇 義亜, 松本 佳則

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 関節リウマチの増悪との鑑別に苦慮した両側踵脆弱性骨折の1例

    氏家 正皓, 片山 祐, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 松本 佳則, 中原 龍一, 那須 義久, 西田 圭一郎, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • Clinical manifestations of SLE SLE患者における代診医師への受診と主治医への信頼度との関連性 TRUMP2-SLEの横断研究(The Association of the visits to substitute physicians and trust in one's physician in SLE patients: a cross-sectional TRUMP2-SLE study)

    Katayama Yu, Miyawaki Yoshia, Shidahara Kenta, Nawachi Shoichi, Asano Yosuke, Ohashi Keiji, Katsuyama Eri, Katsuyama Takayuki, Narazaki Mariko, Matsumoto Yoshinori, Sada Ken-ei, Oguro Nao, Yajima Nobuyuki, Yoshimi Ryusuke, Shimojima Yasuhiro, Wada Jun, Kurita Nobuaki

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：English  

    researchmap

  • COVID-19ワクチン接種後に脊椎関節炎が顕在化した一例

    志田原 健太, 松本 佳則, 松本 和也, 廣瀬 啓, 中土井 崇人, 縄稚 翔一, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 高安動脈炎が疑われたがPET-CTを契機に希少疾患であるシトステロール血症と判明した一例

    中土井 崇人, 勝山 恵理, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 宮脇 義亜, 大橋 敬司, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 臨床(内科)・症例報告 大学病院に勤務する膠原病・リウマチ内科医のバーンアウト(燃え尽き症候群)とグリットとの関連 TRUMP2-SLE研究

    宮脇 義亜, 佐田 憲映, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 大橋 敬司, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 松本 佳則, 小黒 奈緒, 矢嶋 宣幸, 吉見 竜介, 下島 恭弘, 和田 淳, 栗田 宜明

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 爪形成不全と肘関節脱臼を伴った関節リウマチの1例

    増田 倫敦, 松本 佳則, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 動眼神経麻痺を発症した巨細胞性動脈炎の一例

    清水 崇司, 勝山 隆行, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 楢崎 真理子, 佐田 憲映, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 横隔膜挙上に伴う呼吸困難を合併した巨細胞性動脈炎(GCA)の一例

    松岡 雅人, 松本 佳則, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 痛風性関節炎、特発性間質性肺炎発症後に多発脳梗塞を呈した顕微鏡的多発血管炎(MPA)の1例

    堀口 裕紀, 松本 佳則, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 初発から40年後に診断に至った炎症症候持続TNF受容体関連周期性症候群の一例

    高嶋 香菜子, 松本 佳則, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 大型血管炎が疑われた大動脈周囲悪性リンパ腫の1例

    道廣 麻友, 勝山 隆行, 松本 和也, 廣瀬 啓, 志田原 健太, 縄稚 翔一, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 恵理, 楢崎 真理子, 佐田 憲映, 松本 佳則, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • SLEにおける疾患活動性とQOL 全身性エリテマトーデス診療における医師の性格特性と治療目標達成との関連 TRUMP2-SLE研究

    佐田 憲映, 宮脇 義亜, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 大橋 敬司, 勝山 隆行, 勝山 恵理, 楢崎 真理子, 松本 佳則, 小黒 奈緒, 矢嶋 宣幸, 吉見 竜介, 下島 恭弘, 栗田 宜明

    日本リウマチ学会総会・学術集会プログラム・抄録集  2022.3  (一社)日本リウマチ学会

    　More details

    Event date： 2022.3

    Language：Japanese  

    researchmap

  • 胸膜炎を合併したシェーグレン症候群の一例

    大武 春香, 勝山 隆行, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 松本 佳則, 楢崎 真理子, 佐田 憲映, 大塚 文男, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • 大動脈周囲に軟部腫瘤影を認めた多発血管炎性肉芽腫症(GPA)の一例

    末長 理恵, 松本 佳則, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • 二度の急性心筋梗塞を発症した血管ベーチェットの一例

    アサモア・アビ, 勝山 隆行, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 松本 佳則, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • ぎりぎりのタイミングで免疫抑制療法を回避できたMPO-ANCA高値不明熱の一例

    昆 尭明, 松本 佳則, 志田原 健太, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • リウマチ性多発筋痛症(PMR)様の症状を呈した急性リンパ性白血病の1例

    縄稚 翔一, 松本 佳則, 志田原 健太, 中土井 崇人, 浅野 洋介, 片山 祐, 大橋 敬司, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • 多発性筋炎、間質性肺炎治療中に前腕腫脹で判明した転移性結核膿瘍の1例

    上里 祐賀, 松本 佳則, 縄稚 翔一, 大橋 敬司, 志田原 健太, 浅野 洋介, 片山 祐, 林 啓悟, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • 無筋症候性皮膚筋炎治療中に発症した播種性ノカルジア症の一例

    中土井 崇人, 宮脇 義亜, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 森下 美智子, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • SLE・抗リン脂質抗体症候群(臨床):ステロイド 全身性エリテマトーデス患者におけるステロイド中止と罹病期間・慢性障害との関連 LUNAレジストリデータを用いた横断研究

    佐田 憲映, 片山 祐, 浅野 洋介, 林 啓悟, 大橋 敬司, 宮脇 義亜, 勝山 隆行, 楢崎 真理子, 松本 佳則, 矢嶋 宣幸, 吉見 竜介, 下島 恭弘, 大野 滋, 梶山 浩, 一瀬 邦弘, 佐藤 秀三, 藤原 道雄, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • SLE・抗リン脂質抗体症候群(臨床):ステロイド SLE患者における副腎皮質ステロイド投与量と心理的健康観に関する縦断的検討

    宮脇 義亜, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 矢嶋 宣幸, 吉見 竜介, 下島 恭弘, 大野 滋, 梶山 浩, 一瀬 邦弘, 佐藤 秀三, 藤原 道雄, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • 全身性エリテマトーデス(SLE)患者における飲酒習慣と倦怠感との関連 LUNAレジストリを用いた横断研究

    片山 祐, 宮脇 義亜, 浅野 洋介, 林 啓悟, 大橋 敬司, 勝山 隆行, 楢崎 真理子, 松本 佳則, 佐田 憲映, 矢嶋 宣幸, 吉見 竜介, 下島 恭弘, 大野 滋, 梶山 浩, 一瀬 邦弘, 佐藤 秀三, 藤原 道雄, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • 関節リウマチに対しインフリキシマブバイオシミラー製剤を導入後にループス腎炎が生じた一例

    志田原 健太, 勝山 隆行, 縄稚 翔一, 浅野 洋介, 片山 祐, 林 啓悟, 大橋 敬司, 宮脇 義亜, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2021.3  (一社)日本リウマチ学会

    　More details

    Event date： 2021.3

    Language：Japanese  

    researchmap

  • A case of an 18-year-old man who was diagnosed with subcutaneous panniculitis-like T-cell lymphoma

    和田嵩平, 和田嵩平, 和田嵩平, 勝山隆行, 縄稚翔一, 吉田遥, 松本佳則, 三宅智子, 野村隼人, 中井友美, 山崎江利子, 西森久和, 大山矩史, 谷口恒平, 吉野正, 前田嘉信, 森実真, 和田淳

    日本プライマリ・ケア連合学会学術大会(Web)  2021 

    　More details

    Event date： 2021

    Language：Japanese  

    researchmap

  • SLE・抗リン脂質抗体症候群(臨床) 低疾患活動状態(LLDAS)のSLE患者における副腎皮質ステロイド投与量と心理的健康観との関連 LUNAレジストリーを用いた横断研究

    宮脇 義亜, 佐田 憲映, 森下 美智子, 渡辺 晴樹, 松本 佳則, 矢嶋 宣幸, 吉見 竜介, 下島 恭弘, 大野 滋, 梶山 浩, 一瀬 邦弘, 佐藤 秀三, 藤原 道雄, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2020.8  (一社)日本リウマチ学会

    　More details

    Event date： 2020.8

    Language：Japanese  

    researchmap

  • 全身性エリテマトーデスの慢性損傷に対するビタミンD補給の効果 Lupus registry of Nationwide institutions(LUNA)からの横断分析(Effect of vitamin D supplementation of chronic damage in systemic lupus erythematosus: cross-sectional analysis from a lupus registry of nationwide institutions(LUNA))

    Hayashi Keigo, Sada Ken-ei, Asano Yosuke, Katayama Yu, Ohashi Keiji, Morishita Michiko, Watanabe Haruki, Matsumoto Yoshinori, Yajima Nobuyuki, Yoshimi Ryusuke, Shimojima Yasuhiro, Ohno Shigeru, Kajiyama Hiroshi, Ichinose Kunihiro, Sato Shuzo, Fujiwara Michio, Wada Jun

    日本リウマチ学会総会・学術集会プログラム・抄録集  2020.8  (一社)日本リウマチ学会

    　More details

    Event date： 2020.8

    Language：English  

    researchmap

  • 関節リウマチ患者に多発性肺結節を認めた一例

    山村 裕理子, 川畑 智子, 浅野 洋介, 林 啓悟, 平松 澄恵, 森下 美智子, 大橋 敬司, 渡辺 晴樹, 楢崎 真理子, 松本 佳則, 佐田 憲映, 和田 淳

    岡山医学会雑誌  2018.12  岡山医学会

    　More details

    Event date： 2018.12

    Language：Japanese  

    researchmap

  • SLE・抗リン脂質抗体症候群1 全身性エリテマトーデスの妊娠と慢性障害に関する検討

    森下 美智子, 大橋 敬司, 宮脇 義亜, 佐田 憲映, 浅野 洋介, 林 啓悟, 平松 澄恵, 山村 裕理子, 勝山 恵理, 勝山 隆行, 渡辺 晴樹, 楢崎 真理子, 建部 智子, 松本 佳則, 渡部 克枝, 川畑 智子, 矢嶋 宣幸, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2018.3  (一社)日本リウマチ学会

    　More details

    Event date： 2018.3

    Language：Japanese  

    researchmap

  • 炎症性腸疾患関連関節炎の二次無効にアダリムマブ増量が有効であった2症例

    坂本 萌, 松本 佳則, 浅野 洋介, 林 啓悟, 山村 裕理子, 平松 澄恵, 森下 美智子, 大橋 敬司, 宮脇 義亜, 渡辺 晴樹, 川畑 智子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2018.3  (一社)日本リウマチ学会

    　More details

    Event date： 2018.3

    Language：Japanese  

    researchmap

  • 抗MDA5抗体が病勢の指標となったclinically amyopathic dermatomyositisの一例

    今村 竜太, 渡辺 晴樹, 山村 裕理子, 浅野 洋介, 林 啓悟, 平松 澄恵, 大橋 敬司, 宮脇 義亜, 森下 美智子, 雛元 紀和, 建部 智子, 松本 佳則, 川畑 智子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2018.3  (一社)日本リウマチ学会

    　More details

    Event date： 2018.3

    Language：Japanese  

    researchmap

  • 門脈海綿状変化と肉芽腫性精巣上体炎を認めたベーチェット病の一例

    本倉 優美, 渡辺 晴樹, 山村 裕理子, 加納 弓月, 浅野 洋介, 林 啓悟, 平松 澄恵, 大橋 敬司, 宮脇 義亜, 森下 美智子, 雛元 紀和, 建部 智子, 松本 佳則, 川畑 智子, 佐田 憲映, 和田 淳

    日本リウマチ学会総会・学術集会プログラム・抄録集  2018.3  (一社)日本リウマチ学会

    　More details

    Event date： 2018.3

    Language：Japanese  

    researchmap

  • 骨芽細胞分化に対するBMPとERの相互作用の検討

    大塚 文男, 楢崎 真理子, 勝山 隆行, 松本 佳則, 越智 可奈子, 当真 貴志雄, 中村 絵里, 塚本 尚子, 三好 智子, 稲垣 兼一, 小倉 俊郎, 槇野 博史

    日本内分泌学会雑誌  2013.4  (一社)日本内分泌学会

    　More details

    Event date： 2013.4

    Language：Japanese  

    researchmap

  • FGF-8とEstrogenによる乳癌細胞の増殖機転とBMPの関与

    増田 紘子, 大塚 文男, 三好 智子, 山中 龍太郎, 高野 真理子, 松本 佳則, 稲垣 兼一, 平 成人, 槇野 博史, 土井原 博義

    日本内分泌学会雑誌  2011.4  (一社)日本内分泌学会

    　More details

    Event date： 2011.4

    Language：Japanese  

    researchmap

  • ステロイドによる骨芽細胞分化および炎症性骨分化抑制への影響

    松本 佳則, 大塚 文男, 高野 真理子, 向井 知之, 武田 昌也, 三好 智子, 稲垣 兼一, 槇野 博史

    日本内分泌学会雑誌  2010.9  (一社)日本内分泌学会

    　More details

    Event date： 2010.9

    Language：Japanese  

    researchmap

  • 血管炎・APS シクロホスファミド併用ステロイド早期減量プロトコルによるANCA関連血管炎治療の検討

    松本 佳則, 佐田 憲映, 高野 真理子, 山中 龍太郎, 杉山 晃一, 向井 知之, 若林 宏, 川畑 智子, 矢野 隆介, 槇野 博史

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集  2010.3  (一社)日本リウマチ学会

    　More details

    Event date： 2010.3

    Language：Japanese  

    researchmap

  • 骨軟骨と滑膜 BMPによる骨芽細胞分化に対するTNF-αおよびsteroidの作用機序の検討

    松本 佳則, 大塚 文男, 向井 知之, 高野 真理子, 山中 龍太郎, 山下 美鈴, 塚本 尚子, 佐田 憲映, 槇野 博史

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集  2010.3  (一社)日本リウマチ学会

    　More details

    Event date： 2010.3

    Language：Japanese  

    researchmap

  • Dysfunction of Tankyrase causes autoinflammation through activation of the TLR2 signaling pathway.

    第67回日本リウマチ学会総会・学術集会 International Concurrent Workshop  2023.4 

    　More details

  • チロシンキナーゼシグナルネットワークと骨代謝 Invited

    第39回日本骨代謝学会学術集会 研究奨励賞受賞講演  2021.10 

    　More details

  • Reciprocal protein stabilization of ABL and TAZ regulates osteoblastogenesis and embryonic bone development through transcription factor RUNX2

    Yoshinori Matsumoto

    The European Calcified Tissue Society Digital Congress 2021  2021.5 

    　More details

  • 海外留学とそれを活かした研究展開 Invited

    松本佳則

    日本リウマチ学会ベーシックリサーチカンファレンス2020 J-STARセッション  2020.10 

    　More details

  • 関節リウマチとTNF阻害薬、最近の知見 Invited

    松本佳則

    第41回日本炎症・再生医学会 教育講演6  2020.7 

    　More details

  • アダプター蛋白3BP2を取り巻く骨代謝シグナルネットワーク Invited

    松本佳則

    第40回日本骨形態計測学会 シンポジウム（コロナ感染症にて抄録のみ）  2020.6 

    　More details

  • 希少疾患研究から学んだこと、新たな展開へ Invited

    松本佳則

    第37回日本骨代謝学会学術集会 シンポジウム Rising Stars in Skeletal Biology  2019.10 

    　More details

  • New Insight into the Role of the Tankyrase-RNF146-3BP2 Axis for Bone Metabolism Invited

    Yoshinori Matsumoto

    16th Meeting of Bone Biology Forum  2019.8 

    　More details

  • 酵素に着目した関節リウマチ発症機序の解明 Invited

    松本佳則

    日本リウマチ財団 三浦記念リウマチ学術研究賞受賞講演  2019.6 

    　More details

  • E3-Ubiquitin Ligase RNF146 links Bone to Energy Metabolism through regulation of the RUNX2 Transcriptional Activity controlled by the Wnt-FGF18-TAZ Axis

    第63回日本リウマチ学会総会・学術集会 International Concurrent Workshop  2019.4 

    　More details

  • アダプター蛋白3BP2を取り巻くシグナルネットワーク Invited

    松本 佳則

    日本リウマチ学会ベーシックリサーチカンファレンス2018 次世代リーダーセッション  2018.11 

    　More details

  • New Insight into the Role of the Tankyrase-RNF146-3BP2 Axis for Bone Metabolism Invited

    Yoshinori Matsumoto

    Asia Pacific Bone Academy in Taipei  2018.11 

    　More details

  • 希少疾患研究から学んだこと、新たな展開へ

    松本 佳則

    日本骨代謝学会 Skeletal Science Retreat 2018  2018.11 

    　More details

  • 自然免疫、骨代謝を制御する新たなメカニズムの解明

    松本 佳則

    第46回日本臨床免疫学会総会  2018.11 

    　More details

  • Reciprocal stabilization of ABL and TAZ is required for osteoblastogenesis and embryonic bone development controlled by the master transcription factor RUNX2

    Yoshinori Matsumoto

    日本リウマチ学会 International School 2018  2018.8 

    　More details

  • 骨粗鬆症克服を目指した 転写因子RUNX2活性化メカニズムの解明

    松本 佳則

    第36回日本骨代謝学会学術集会  2018.7 

    　More details

  • Repression of the E3-Ubiquitin Ligase RNF146 by RANKL Integrates Multiple Pathways Controlling Osteoclastogenesis

    Yoshinori Matsumoto

    第62回日本リウマチ学会総会・学術集会 International Workshop  2018.4 

    　More details

  • Bone is Dynamic! 希少疾患研究から始まった新たな挑戦 Invited

    松本佳則

    第17回 Bio Forum at Dental School  2018.4 

    　More details

  • Bone is Dynamic ! 希少疾患研究から始まった 骨免疫制御機構解明への挑戦

    松本 佳則

    日本臨床免疫学会 Midwinter Seminar 2018  2018.2 

    　More details

  • Bone is Dynamic! 希少疾患研究から始まった骨免疫制御機構解明への挑戦

    松本 佳則

    第4回日本リウマチ学会ベーシックリサーチカンファレンス  2017.10 

    　More details

  • Reciprocal protein stabilization of ABL and TAZ regulates osteoblastogenesis and embryonic bone development through transcription factor RUNX2

    Yoshinori Matsumoto

    第61回日本リウマチ学会総会・学術集会 International Workshop  2017.4 

    　More details

▼display all

Awards

  • 第7回岡山テックプラングランプリ リアルテックファンド賞

    2025  

    　More details

  • 第67回日本リウマチ学会総会・学術集会 ICW Excellent Abstract Award

    2023  

    　More details

  • 学術奨励賞

    2021   宇部興産学術振興財団  

    　More details

  • 研究奨励賞

    2021   日本骨粗鬆症学会  

    　More details

  • 研究奨励賞

    2021   日本骨代謝学会  

    　More details

  • 中山賞奨励賞

    2021   中山人間科学振興財団  

    　More details

  • 三浦記念リウマチ学術研究賞

    2019   日本リウマチ財団  

    　More details

  • The JSBMR Rising Stars Award

    2019   日本骨代謝学会  

    　More details

  • 日本リウマチ学会奨励賞

    2018  

    　More details

    Country：Japan

    researchmap

  • 第62回日本リウマチ学会総会・学術集会 ICW Excellent Abstract Award

    2018  

    　More details

    Country：Japan

    researchmap

  • 学術奨励賞

    2018   近藤記念医学財団  

    　More details

  • 生物学研究奨励賞

    2018   両備檉園（ていえん）記念財団  

    　More details

  • 第61回日本リウマチ学会総会・学術集会 International Workshop Award

    2017  

    　More details

    Country：Japan

    researchmap

  • 第4回日本リウマチ学会 ベーシックリサーチカンファレンス 優秀演題賞

    2017  

    　More details

    Country：Japan

    researchmap

  • University of Toronto, Research Competition Podium Presentation

    2016  

    　More details

  • 日本学術振興会 海外特別研究員

    2014  

    　More details

    Country：Japan

    researchmap

  • 岡山大学大学院 腎・免疫・内分泌代謝内科学講座 同門会賞

    2013  

    　More details

    Country：Japan

    researchmap

  • 岡山大学大学院 腎・免疫・内分泌代謝内科学講座 同門会賞

    2012  

    　More details

    Country：Japan

    researchmap

  • 日本リウマチ財団海外留学助成

    2011  

    　More details

    Country：Japan

    researchmap

  • 中山人間科学振興財団海外留学助成

    2011  

    　More details

    Country：Japan

    researchmap

  • 住友生命福祉文化財団海外留学助成

    2011  

    　More details

    Country：Japan

    researchmap

  • 岡山大学大学院 腎・免疫・内分泌代謝内科学講座 同門会賞

    2010  

    　More details

    Country：Japan

    researchmap

▼display all

Research Projects

  • Development of Next-Generation Therapeutics for Systemic Lupus Erythematosus Utilizing Biobanks and National Registries

    Grant number：25K02687  2025.04 - 2028.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    松本 佳則, 石垣 和慶, 今井 祐記, 宮脇 義亜, 中野 正博, 竹田 浩之, 林 啓悟, 山中 聡士, 藤尾 圭志, 佐田 憲映, 鍔田 武志

    　 More details

    Grant amount：\18720000 （ Direct expense: \14400000 、 Indirect expense：\4320000 ）

    researchmap

  • AMED難治性疾患研究事業・ 医薬品ステップ0

    2025 - 2028

    国立研究開発法人日本医療研究開発機構 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 科学研究費助成事業・ 基盤研究（B）

    2025 - 2028

    日本学術振興会 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • G-7奨学財団 令和７年度研究開発助成事業

    2025 - 2026

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 2024年度 橋渡し研究戦略的推進プログラム

    2024 - 2025

    国立研究開発法人日本医療研究開発機構 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • テルモ生命科学振興財団 2024年度Ⅲ研究助成

    2024 - 2025

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 先進医薬振興財団 血液一般研究助成

    2024 - 2025

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 日本応用酵素協会 2024年度酵素研究助成

    2024 - 2025

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 痛風・尿酸財団 2024年度研究助成

    2024 - 2025

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 関節リウマチの精密医療の推進に資する研究推進プログラム研究助成

    2023 - 2025

    日本リウマチ学会 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 三菱財団 第54回自然科学研究助成

    2023 - 2024

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 持田記念医学薬学振興財団 2023年度研究助成

    2023 - 2024

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 愛媛大学プロテオサイエンスセンター 共同研究助成

    2023 - 2024

    　 More details

    Authorship：Coinvestigator(s) 

    researchmap

  • 細胞内蛋白の代謝異常に着目した骨粗鬆症発症機序の解明と新規治療ターゲットの開発

    Grant number：22K08625  2022 - 2025

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    松本 佳則

    　 More details

    Authorship：Principal investigator 

    Grant amount：\4290000 （ Direct expense: \3300000 、 Indirect expense：\990000 ）

    researchmap

  • AMED 創薬ブースター

    2022 - 2023

    国立研究開発法人日本医療研究開発機構 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 2021年度 橋渡し研究戦略的推進プログラム（継続）

    2021 - 2022

    国立研究開発法人日本医療研究開発機構 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • テルモ生命科学振興財団 2021年度研究開発助成

    2021 - 2022

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 宇部興産学術振興財団 第61回学術奨励賞

    2021 - 2022

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 2021年度 東京医科歯科大学難治疾患共同研究助成

    2021 - 2022

    　 More details

    Authorship：Coinvestigator(s) 

    researchmap

  • 愛媛大学プロテオサイエンスセンター 共同研究助成

    2021 - 2022

    　 More details

  • 武⽥科学振興財団 2020年度 生命科学研究助成

    2020 - 2023

    　 More details

    Authorship：Principal investigator 

    researchmap

  • AMED 臨床研究・治験推進研究事業

    2020 - 2022

    国立研究開発法人日本医療研究開発機構 

    　 More details

    Authorship：Coinvestigator(s) 

    researchmap

  • 2020年度 橋渡し研究戦略的推進プログラム

    2020 - 2021

    国立研究開発法人日本医療研究開発機構 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • Abbvie 研究助成

    2020 - 2021

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 愛媛大学プロテオサイエンスセンター 共同研究助成

    2020 - 2021

    　 More details

    Authorship：Coinvestigator(s) 

    researchmap

  • 2020年度 東京医科歯科大学難治疾患共同研究助成

    2020 - 2021

    　 More details

    Authorship：Coinvestigator(s) 

    researchmap

  • 令和２年度岡山大学次世代研究育成グループ支援

    2020 - 2021

    　 More details

  • 東レ科学振興会 第60回（令和元年度）科学技術研究助成

    2019 - 2022

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 第一三共製薬 共同研究助成 第９回「TaNeDS」

    2019 - 2021

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 高松宮妃癌研究基金 令和元年度（第５1回）研究助成

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 日本骨代謝学会 若手研究者助成（The JSBMR Rising Stars Grant）

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 日本応用酵素協会 酵素研究助成

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • Abbvie 研究助成

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 大和証券ヘルス財団 令和元年度（第４６回）調査研究助成

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 日本アレルギー協会 真鍋奨学助成

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 日立財団 2019年度（第51回）倉田奨励金

    2019 - 2020

    　 More details

  • 第一三共生命科学研究振興財団 2019 年度（第37 回）研究助成

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 先進医薬研究振興財団 平成31年度 血液医学分野 一般研究助成

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 三井住友海上福祉財団 研究助成

    2019 - 2020

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 岡山医学振興会 研究助成

    2019 - 2020

    　 More details

  • 愛媛大学プロテオサイエンスセンター 共同研究助成

    2019 - 2020

    　 More details

  • 岡山県健康づくり財団 がんに関する研究・研修助成金

    2019 - 2020

    　 More details

  • 日本リウマチ財団 三浦記念リウマチ学術研究賞

    2018 - 2019

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 日本ワックスマン財団 平成30年度学術研究助成

    2018 - 2019

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 沖中記念成人病研究所 2019年度研究費助成

    2018 - 2019

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 骨粗鬆症財団 第14回（平成30年度）リリー研究助成（骨領域研究）

    2018 - 2019

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 川崎医学・医療福祉学振興会 平成30年度教育研究助成

    2018 - 2019

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 近藤記念医学財団 平成30年度学術奨励賞

    2018 - 2019

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 両備檉園記念財団 平成30年度生物学研究奨励賞

    2018 - 2019

    　 More details

    Authorship：Principal investigator 

    researchmap

  • Investigation of the molecular mechanism of inflammation and bone metabolism.

    Grant number：17H06883  2017.08 - 2019.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Research Activity Start-up

    Matsumoto Yoshinori, He Fang

    　 More details

    Grant amount：\2730000 （ Direct expense: \2100000 、 Indirect expense：\630000 ）

    We uncover that protein A controls cytokine production. Protein A serves as a major checkpoint regulator of cytokine production and inflammation. Our present data demonstrate that protein A regulate cytokine production through regulation of the TLR signaling pathway, leading to the therapeutic target for autoinflammatory diseases.

    researchmap

  • 三井住友海上福祉財団 2017年度研究助成

    2017 - 2018

    　 More details

  • 中冨健康科学振興財団 平成29年度（第30回）研究助成

    2017 - 2018

    　 More details

  • 難病医学研究財団 平成29年度医学研究奨励助成

    2017 - 2018

    　 More details

    Authorship：Principal investigator 

    researchmap

  • ライフサイエンス振興財団 平成29年度研究助成

    2017 - 2018

    　 More details

  • 上原記念生命科学財団 平成29 年度 研究奨励金

    2017 - 2018

    　 More details

  • 神澤医学研究振興財団 平成29年度（第21回）研究助成

    2017 - 2018

    　 More details

  • 千里ライフサイエンス振興財団 2017年度岸本基金研究助成

    2017 - 2018

    　 More details

  • 岡山大学若手研究者育成支援事業

    2017 - 2018

    　 More details

  • かなえ医薬振興財団 平成29年度（第46回）研究助成

    2017 - 2018

    　 More details

  • 先進医学振興財団 平成29年度先進研究助成

    2017 - 2018

    　 More details

  • 金原一郎記念医学医療振興財団 第32回基礎医学医療研究助成

    2017 - 2018

    　 More details

  • ノバルティス科学振興財団 第31回 ノバルティス研究奨励金 平成29年度

    2017 - 2018

    　 More details

  • 小林国際奨学財団第6回（平成29年度）研究助成

    2017 - 2018

    　 More details

  • 日本応用酵素協会 2017年度全身性炎症疾患の病因・病態の解明に関する研究助成

    2017 - 2018

    　 More details

  • 持田記念医学薬学振興財団 平成29年度研究助成

    2017 - 2018

    　 More details

  • アステラス病態代謝研究会 平成29年度研究助成

    2017 - 2018

    　 More details

▼display all

 

Class subject in charge

  • Immunology （2024academic year） special  - その他

  • Practicals: Nephrology, Rheumatology, Endocrinology and Metabolism （2024academic year） special  - その他

  • Research Projects: Nephrology, Rheumatology, Endocrinology and Metabolism （2024academic year） special  - その他

  • Research and Practicals: Nephrology, Rheumatology, Endocrinology and Metabolism I （2024academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism I （2024academic year） special  - その他

  • Research and Practicals:Nephrology, Rheumatology, Endocrinology and Metabolism II （2024academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism II （2024academic year） special  - その他

  • Practicals: Nephrology, Rheumatology, Endocrinology and Metabolism （2023academic year） special  - その他

  • Research Projects: Nephrology, Rheumatology, Endocrinology and Metabolism （2023academic year） special  - その他

  • Research and Practicals: Nephrology, Rheumatology, Endocrinology and Metabolism I （2023academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism I （2023academic year） special  - その他

  • Research and Practicals:Nephrology, Rheumatology, Endocrinology and Metabolism II （2023academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism II （2023academic year） special  - その他

  • advanced medical sciences （2022academic year） Prophase  - 不開講

  • Internal Medicine （2022academic year） 1st and 2nd semester  - [第１学期]月4,月5,水6, [第２学期]月4,月5,金6

  • Research and Practicals: Nephrology, Rheumatology, Endocrinology and Metabolism I （2022academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism I （2022academic year） special  - その他

  • Research and Practicals:Nephrology, Rheumatology, Endocrinology and Metabolism II （2022academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism II （2022academic year） special  - その他

  • advanced medical sciences （2021academic year） Prophase  - その他

  • Internal Medicine （2021academic year） 1st and 2nd semester  - [第１学期]月4,月5,水6, [第２学期]月4,月5,金6

  • Research Projects and Practicals: Medicine and Clinical Science I （2021academic year） special  - その他

  • Research and Practicals: Nephrology, Rheumatology, Endocrinology and Metabolism I （2021academic year） special  - その他

  • Research and Practicals: Nephrology, Rheumatology, Endocrinology and Metabolism I （2021academic year） special  - その他

  • Lecture and Research Projects: Medicine and Clinical Science I （2021academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism I （2021academic year） special  - その他

  • Research Projects and Practicals: Medicine and Clinical Science II （2021academic year） special  - その他

  • Lecture and Research Projects: Medicine and Clinical Science II （2021academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism II （2021academic year） special  - その他

  • Internal Medicine （2020academic year） 1st and 2nd semester  - [第１学期]月4,月5,水6, [第２学期]月4,月5,金6

  • Research Projects and Practicals: Medicine and Clinical Science I （2020academic year） special  - その他

  • Research and Practicals: Nephrology, Rheumatology, Endocrinology and Metabolism I （2020academic year） special  - その他

  • Lecture and Research Projects: Medicine and Clinical Science I （2020academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism I （2020academic year） special  - その他

  • Research Projects and Practicals: Medicine and Clinical Science II （2020academic year） special  - その他

  • Research and Practicals:Nephrology, Rheumatology, Endocrinology and Metabolism II （2020academic year） special  - その他

  • Lecture and Research Projects: Medicine and Clinical Science II （2020academic year） special  - その他

  • Lecture and Research: Nephrology, Rheumatology, Endocrinology and Metabolism II （2020academic year） special  - その他

▼display all